101
|
Abstract
SARS-CoV-2 is the viral agent of COVID-19, a pandemic that surfaced in 2019. Although predominantly a respiratory ailment, patients with COVID-19 can have gastrointestinal (GI) and hepatobiliary manifestations. These manifestations are often mild and transient, but they can be severe and consequential. In the GI tract, ischemic enterocolitis is the most common and significant consequence of COVID-19. In the liver, the reported pathologic findings may often be related to consequences of severe systemic viral infection, but reports of hepatitis presumed to be due to SARS-CoV-2 suggest that direct viral infection of the liver may be a rare complication of COVID-19. In both the GI tract and liver, lingering symptoms of GI or hepatic injury after resolution of pulmonary infection may be part of the evolving spectrum of long COVID.
Collapse
Affiliation(s)
- Angela R Shih
- Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
| | - Joseph Misdraji
- Department of Pathology, Yale New Haven Hospital, Yale University, New Haven, CT, 06510, USA.
| |
Collapse
|
102
|
Gupta T, Sharma H. COVID-19 and the liver: Are footprints still there? World J Gastroenterol 2023; 29:656-669. [PMID: 36742164 PMCID: PMC9896610 DOI: 10.3748/wjg.v29.i4.656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Revised: 10/13/2022] [Accepted: 11/21/2022] [Indexed: 01/20/2023] Open
Abstract
The coronavirus disease 2019 (COVID-19) hit the entire world as a global pandemic and soon became the most important concern for all patients with chronic diseases. An early trend in higher mortality in patients with acute respiratory distress attracted all researchers to closely monitor patients for the involvement of other systems. It soon became apparent that patients with chronic liver diseases are at increased risk of mortality given their cirrhosis-associated immune dysfunction. Additionally, liver function abnormalities were noted in patients with severe COVID-19. Profound cytokine storm, direct viral infection, drugs and reactivation of viral infections were causes of deranged liver functions. Here, we discuss the relation between COVID-19 and chronic liver disease, specifically cirrhosis, hepatitis B, hepatitis C, and non-alcoholic fatty liver disease (NAFLD), as well as the liver manifestations of COVID-19. The metabolic syndrome, obesity, diabetes mellitus and NAFLD were found to worsen outcome in different studies reported worldwide. Decompensated cirrhosis should be considered a risk factor for death and severe COVID-19. Recently, COVID-19 related cholangiopathy has also been reported with changes of secondary sclerosing cholangitis. The long-term persistence of viral antigens in gut epithelia raises concern regarding the future risk of autoimmune liver diseases.
Collapse
Affiliation(s)
- Tarana Gupta
- Department of Medicine, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak 124001, Haryana, India
| | - Hemant Sharma
- Department of Medicine, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak 124001, Haryana, India
| |
Collapse
|
103
|
Farias JP, Codes L, Vinhaes D, Amorim AP, D’Oliveira RC, Farias AQ, Bittencourt PL. Impact of baseline abnormal liver enzymes in the outcome of COVID-19 infection. Transl Gastroenterol Hepatol 2023; 8:5. [PMID: 36704646 PMCID: PMC9813650 DOI: 10.21037/tgh-22-41] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/24/2022] [Accepted: 10/11/2022] [Indexed: 11/07/2022] Open
Abstract
Background Little is known about the significance of liver function tests (LFT) abnormalities in COVID-19 and their impact on disease outcomes. The aims of the study were to evaluate abnormalities of LFT in patients with COVID-19 and their impact on disease severity, mortality, and correlation with leukocyte markers of inflammation. Methods All patients with COVID-19 admitted to the emergency department (ED) of a single reference center were retrospectively evaluated. Data were collected using an electronic medical database covering the following variables: demographics, baseline complete blood count (CBC) and ratios, neutrophil-lymphocyte (NLR) and monocyte-lymphocyte ratios (MLR), systemic immune-inflammation index (SII), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels. Disease severity was defined by the presence of organ failure (OF) or requirement for intensive care unit (ICU) support. Mortality was considered as patient death during hospitalization. Results A total of 1,539 subjects (799 women, mean age 57±18 years) with COVID-19 were evaluated. Abnormal AST and/or ALT were seen in 50% of them, with a frequency and magnitude that significantly correlated with leukocyte count and ratios. Both LFT were significantly associated with requirement for hospital and ICU admission and mortality. High AST levels were significantly associated with the presence, number, and types of OFs and in-hospital length of stay (LOS). Elevated ALT was also significantly associated with the aforementioned variables, with the exception of OFs presence, circulatory failure and LOS. Conclusions LFT abnormalities are frequently seen in COVID-19 patients, reflect SARS-CoV-2 associated inflammation and may predict adverse outcomes. LFT may be useful to aid decision-making in the ED for hospital admission or scheduled outpatient reevaluation.
Collapse
Affiliation(s)
| | - Liana Codes
- Portuguese Hospital of Bahia, Salvador, Bahia, Brazil;,Bahiana School of Medicine and Public Health, Salvador, Bahia, Brazil
| | - Diana Vinhaes
- Portuguese Hospital of Bahia, Salvador, Bahia, Brazil
| | | | - Ricardo Cruz D’Oliveira
- Portuguese Hospital of Bahia, Salvador, Bahia, Brazil;,Bahiana School of Medicine and Public Health, Salvador, Bahia, Brazil
| | | | - Paulo Lisboa Bittencourt
- Portuguese Hospital of Bahia, Salvador, Bahia, Brazil;,Bahiana School of Medicine and Public Health, Salvador, Bahia, Brazil
| |
Collapse
|
104
|
Parchwani D, Sonagra AD, Dholariya S, Motiani A, Singh R. COVID-19-related liver injury: Focus on genetic and drug-induced perspectives. World J Virol 2023; 12:53-67. [PMID: 36743658 PMCID: PMC9896591 DOI: 10.5501/wjv.v12.i1.53] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Revised: 10/15/2022] [Accepted: 12/01/2022] [Indexed: 01/18/2023] Open
Abstract
BACKGROUND Empirical use of potentially hepatotoxic drugs in the management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is considered as one of the major etiopathogenetic factors for liver injury. Recent evidence has shown that an underlying genetic factor may also occur. Hence, it is important to understand the host genetics and iatrogenic-based mechanisms for liver dysfunction to make timely remedial measures.
AIM To investigate drug-induced and genetic perspectives for the development of coronavirus disease 2019 (COVID-19)-related liver injury.
METHODS Reference Citation Analysis, PubMed, Google Scholar and China National Knowledge Infrastructure were searched by employing the relevant MeSH keywords and pertaining data of the duration, site and type of study, sample size with any subgroups and drug-induced liver injury outcome. Genetic aspects were extracted from the most current pertinent publications.
RESULTS In all studies, the hepatic specific aminotransferase and other biochemical indices were more than their prescribed upper normal limit in COVID-19 patients and were found to be significantly related with the gravity of disease, hospital stay, number of COVID-19 treatment drugs and worse clinical outcomes. In addition, membrane bound O-acyltransferase domain containing 7 rs641738, rs11385942 G>GA at chromosome 3 gene cluster and rs657152 C>A at ABO blood locus was significantly associated with severity of livery injury in admitted SARS-CoV-2 patients.
CONCLUSION Hepatic dysfunction in SARS-CoV-2 infection could be the result of individual drugs or due to drug-drug interactions and may be in a subset of patients with a genetic propensity. Thus, serial estimation of hepatic indices in hospitalized SARS-CoV-2 patients should be done to make timely corrective actions for iatrogenic causes to avoid clinical deterioration. Additional molecular and translational research is warranted in this regard.
Collapse
Affiliation(s)
- Deepak Parchwani
- Department of Biochemistry, All India Institute of Medical Sciences, Rajkot 360001, India
| | - Amit D Sonagra
- Department of Biochemistry, All India Institute of Medical Sciences, Rajkot 360001, India
| | - Sagar Dholariya
- Department of Biochemistry, All India Institute of Medical Sciences, Rajkot 360001, India
| | - Anita Motiani
- Department of Biochemistry, All India Institute of Medical Sciences, Rajkot 360001, India
| | - Ragini Singh
- Department of Biochemistry, All India Institute of Medical Sciences, Rajkot 360001, India
| |
Collapse
|
105
|
Histology and cytokine levels in hepatic injury accompanying a case of non-severe COVID-19. Clin J Gastroenterol 2023; 16:270-278. [PMID: 36690911 PMCID: PMC9870769 DOI: 10.1007/s12328-023-01755-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Accepted: 01/03/2023] [Indexed: 01/25/2023]
Abstract
The pathogenesis of liver dysfunction that complicates coronavirus disease 2019 (COVID-19) remains unclear, especially in mild to moderate severity cases. In this case, a novel coronavirus infection was detected by polymerase chain reaction (PCR) in a 76-year-old woman hospitalized after presenting with fever. No other abnormal physical findings were observed, and oxygen administration was not required. Chest computed tomography (CT) showed a ground-glass-like and an infiltrative shadow in the right lung, and moderate COVID-19 was diagnosed. Initially, the fever resolved, and PCR turned negative; however, the fever reappeared on hospitalization day 14, and CT showed pneumonia exacerbation accompanied by new onset of fatty liver. Biochemical testing revealed marked liver dysfunction, accompanied by elevated serum interleukin (IL)-6, IL-10, and tumor necrosis factor-α levels. Physical findings and all laboratory parameters improved after conservative treatment, and she was discharged on day 22. A liver biopsy performed 44 days post-discharge showed T-cell-dominant inflammatory cell infiltration, mainly in the portal region. Some hepatocytes showed fatty degeneration.We report a case of moderate COVID-19 in which histological hepatitis persisted after a substantial period had passed since the initial infection had cleared and associated transaminase elevations had resolved, with a comparison of serum cytokine dynamics.
Collapse
|
106
|
Alva NV, Méndez OR, Gasca JC, Salvador I, Hernández N, Valdez M. [Liver injury due to COVID-19 in critically ill adult patients. A retrospective study]. REVISTA DE GASTROENTEROLOGIA DE MEXICO 2023:S0375-0906(23)00002-2. [PMID: 36684811 PMCID: PMC9842624 DOI: 10.1016/j.rgmx.2022.08.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/21/2022] [Accepted: 08/25/2022] [Indexed: 01/19/2023]
Abstract
INTRODUCTION AND AIM Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged, causing the current pandemic of acute respiratory disease known as COVID-19. Liver injury due to COVID-19 is defined as any liver injury occurring during the course of the disease and treatment of patients with COVID-19, with or without liver disease. The incidence of elevated liver transaminases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), ranges from 2.5 to 76.3%. The aim of the present study was to describe the hepatic biochemical abnormalities, after a SARS-CoV-2-positive polymerase chain reaction (PCR) test, and the mortality rate in critically ill patients. MATERIALS AND METHODS A retrospective study was conducted that included 70 patients seen at a private hospital in Mexico City, within the time frame of February-December 2021. Median patient age was 44.5 years (range: 37-57.2) and 43 (61.4%) of the patients were men. Liver function tests were performed on the patients at hospital admission. RESULTS Gamma glutamyl transferase (GGT) levels were elevated (p = 0.032), as were those of AST (p = 0.011) and ALT (p = 0.021). The patients were stratified into age groups: 18-35, 36-50, and > 50 years of age. The 18 to 35-year-olds had the highest liver enzyme levels and transaminase levels were higher, the younger the patient. Due to the low mortality rate (one patient whose death did not coincide with a hepatic cause), the multivariate analysis showed an R2 association of 0.689, explained by AST, GGT, and C-reactive protein levels. CONCLUSIONS Despite the increase in transaminases in our study population during the course of COVID-19, there was no increase in mortality. Nevertheless, hospitalized patient progression should be continuously followed.
Collapse
Affiliation(s)
- N V Alva
- Departamento de Terapia Intensiva, Hospital Ángeles Mocel, México
| | - O R Méndez
- Departamento de Medicina Interna, Hospital Star Médica Centro, México
| | - J C Gasca
- Departamento de Terapia Intensiva, Hospital Juárez de México, México
| | - I Salvador
- Departamento de Terapia Intensiva, Hospital Ángeles Mocel, México
| | - N Hernández
- Departamento de Inhaloterapia, Centro Médico ABC, México
| | - Ma Valdez
- Departamento de Terapia Intensiva, Hospital Bicentenario, Aguascalientes, México
| |
Collapse
|
107
|
Baldelli L, Marjot T, Barnes E, Barritt AS, Webb GJ, Moon AM. SARS-CoV-2 Infection and Liver Disease: A Review of Pathogenesis and Outcomes. Gut Liver 2023; 17:12-23. [PMID: 36457261 PMCID: PMC9840920 DOI: 10.5009/gnl220327] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2022] [Revised: 08/31/2022] [Accepted: 09/07/2022] [Indexed: 12/03/2022] Open
Abstract
The impact of the coronavirus disease 2019 (COVID-19) pandemic has been immense, and it continues to have lasting repercussions. While the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus primarily infects the respiratory system, other organ systems are affected, including the liver. Scientific knowledge on the role of SARS-CoV-2 infection and liver injury has evolved rapidly, with recent data suggesting specific hepatotropism of SARS-CoV-2. Moreover, additional concerns have been raised in regard to long-term liver damage, related to emerging cases of post-COVID-19 cholangiopathy and chronic cholestasis. Great effort has also been focused on studying how specific subpopulations with chronic medical conditions might be disproportionately impacted by COVID-19. One such population includes individuals with chronic liver disease (CLD) and cirrhosis, with an expanding body of research indicating these patients being particularly susceptible to adverse outcomes. In this review, we provide an updated summary on the current pathogenesis and mechanism of liver injury in the setting of SARS-CoV-2 infection, the association between health outcomes and SARS-CoV-2 infection in patients with CLD, and the unique consequences of the COVID-19 pandemic on the routine care of patients with CLD.
Collapse
Affiliation(s)
- Luke Baldelli
- Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, NC, USA
| | - Thomas Marjot
- Oxford Liver Unit, Translational Gastroenterology Unit, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK
| | - Eleanor Barnes
- Oxford Liver Unit, Translational Gastroenterology Unit, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK
| | - A. Sidney Barritt
- Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, NC, USA
| | - Gwilym J. Webb
- Cambridge Liver Unit, Addenbrooke's Hospital, Cambridge, UK
| | - Andrew M. Moon
- Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, NC, USA
| |
Collapse
|
108
|
Papagiouvanni I, Kotoulas SC, Pataka A, Spyratos DG, Porpodis K, Boutou AK, Papagiouvannis G, Grigoriou I, Vettas C, Goulis I. COVID-19 and liver injury: An ongoing challenge. World J Gastroenterol 2023; 29:257-271. [PMID: 36687117 PMCID: PMC9846934 DOI: 10.3748/wjg.v29.i2.257] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/12/2022] [Revised: 11/29/2022] [Accepted: 12/21/2022] [Indexed: 01/06/2023] Open
Abstract
The new coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in December 2019, in Wuhan, China. The virus was rapidly spread worldwide, causing coronavirus disease 2019 (COVID-19) pandemic. Although COVID-19 is presented, usually, with typical respiratory symptoms (i.e., dyspnea, cough) and fever, extrapulmonary manifestations are also encountered. Liver injury is a common feature in patients with COVID-19 and ranges from mild and temporary elevation of liver enzymes to severe liver injury and, even, acute liver failure. The pathogenesis of liver damage is not clearly defined; multiple mechanisms contribute to liver disorder, including direct cytopathic viral effect, cytokine storm and immune-mediated hepatitis, hypoxic injury, and drug-induced liver toxicity. Patients with underlying chronic liver disease (i.e., cirrhosis, non-alcoholic fatty liver disease, alcohol-related liver disease, hepatocellular carcinoma, etc.) may have greater risk to develop both severe COVID-19 and further liver deterioration, and, as a consequence, certain issues should be considered during disease management. The aim of this review is to present the prevalence, clinical manifestation and pathophysiological mechanisms of liver injury in patients with SARS-CoV-2 infection. Moreover, we overview the association between chronic liver disease and SARS-CoV-2 infection and we briefly discuss the management of liver injury during COVID-19.
Collapse
Affiliation(s)
- Ioanna Papagiouvanni
- Fourth Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki 54642, Thessaloniki, Greece
| | | | - Athanasia Pataka
- Department of Respiratory Medicine, G Papanikolaou Hospital, Resp Failure Unit, Aristotle University of Thessaloniki, Thessaloniki 57001, Greece
| | - Dionisios G Spyratos
- Pulmonary Department, Aristotle University of Thessaloniki, Thessaloniki 57001, Greece
| | - Konstantinos Porpodis
- Pulmonary Department, Aristotle University of Thessaloniki, Thessaloniki 57001, Greece
| | - Afroditi K Boutou
- Pulmonary Department, G Papanikolaou Hospital, Resp Failure Unit, Aristotle University of Thessaloniki, Thessaloniki 54642, Greece
| | - Georgios Papagiouvannis
- Department of Pharmacy, School of Health Sciences, Frederick University, Nicosia 1036, Cyprus
| | - Ioanna Grigoriou
- Respiratory Failure Clinic, Papanikolaou General Hospital, Thessloniki 57001, Greece
| | - Christos Vettas
- Fourth Department of Internal Medicine, Hippokration General Hospital, Thessaloniki 54642, Greece
| | - Ioannis Goulis
- Fourth Department of Internal Medicine, Hippokration General Hospital, Thessaloniki 54642, Greece
| |
Collapse
|
109
|
Zhao SW, Li YM, Li YL, Su C. Liver injury in COVID-19: Clinical features, potential mechanisms, risk factors and clinical treatments. World J Gastroenterol 2023; 29:241-256. [PMID: 36687127 PMCID: PMC9846943 DOI: 10.3748/wjg.v29.i2.241] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Revised: 11/11/2022] [Accepted: 12/08/2022] [Indexed: 01/06/2023] Open
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has been a serious threat to global health for nearly 3 years. In addition to pulmonary complications, liver injury is not uncommon in patients with novel COVID-19. Although the prevalence of liver injury varies widely among COVID-19 patients, its incidence is significantly increased in severe cases. Hence, there is an urgent need to understand liver injury caused by COVID-19. Clinical features of liver injury include detectable liver function abnormalities and liver imaging changes. Liver function tests, computed tomography scans, and ultrasound can help evaluate liver injury. Risk factors for liver injury in patients with COVID-19 include male sex, preexisting liver disease including liver transplantation and chronic liver disease, diabetes, obesity, and hypertension. To date, the mechanism of COVID-19-related liver injury is not fully understood. Its pathophysiological basis can generally be explained by systemic inflammatory response, hypoxic damage, ischemia-reperfusion injury, and drug side effects. In this review, we systematically summarize the existing literature on liver injury caused by COVID-19, including clinical features, underlying mechanisms, and potential risk factors. Finally, we discuss clinical management and provide recommendations for the care of patients with liver injury.
Collapse
Affiliation(s)
- Shu-Wu Zhao
- Department of Anesthesiology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha 410013, Hunan Province, China
| | - Yi-Ming Li
- School of Basic Medical Science, Naval Medical University/Second Military University, Shanghai 200433, China
| | - Yi-Lin Li
- Department of Pathology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha 410013, Hunan Province, China
| | - Chen Su
- Department of Anesthesiology and Pain, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha 410013, Hunan Province, China
| |
Collapse
|
110
|
Al-Rawi TSS, Al-Ani RM. Liver dysfunction-related COVID-19: A narrative review. World J Meta-Anal 2023; 11:5-17. [DOI: 10.13105/wjma.v11.i1.5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/09/2022] [Revised: 11/25/2022] [Accepted: 12/14/2022] [Indexed: 01/11/2023] Open
Abstract
The coronavirus 2019 disease (COVID-19) is caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2. This disease was designated by the World Health Organization as a pandemic on March 11, 2020, which is not seen before. There are no classical features among the cases of the disease owing to the involvement of nearly all body tissues by the virus. Hepatic involvement is one of the characteristics of the COVID-19 course. There are six possible mechanisms of such involvement: Direct virus injury, drug-induced effect, inflammatory cytokine storm, hypoxia-ischemic destruction, abnormalities in liver function tests, and pre-existing chronic liver diseases. Liver abnormalities are seen commonly in the severe or critical stage of COVID-19. Therefore, these abnormalities determine the COVID-19 severity and carry a high rate of morbidity and mortality. The elderly and patients with comorbidities like diabetes mellitus and hypertension are more vulnerable to liver involvement. Another issue that needs to be disclosed is the liver manifestations following the COVID-19 vaccination, such as autoimmune hepatitis. Of note, complete vaccination with third and fourth booster doses is necessary for patients with previous chronic liver diseases or those who have been subjected to liver transplantation. This review aims to explore the various aspects of liver dysfunction during the COVID-19 course regarding the epidemiological features, predisposing factors, pathophysiological mechanisms, hepatic manifestations due to COVID-19 or following vaccination, role of liver function tests in the assessment of COVID-19 severity, adverse effects of the therapeutic agents for the disease, and prognosis.
Collapse
Affiliation(s)
- Taghreed S Saeed Al-Rawi
- Department of Biochemistry, University of Anbar College of Medicine, Ramadi City 31001, Anbar, Iraq
| | - Raid M Al-Ani
- Department of Surgery/Otolaryngology, University of Anbar College of Medicine, Ramadi City 31001, Anbar, Iraq
| |
Collapse
|
111
|
Jiang L, An X, Duan Y, Lian F, Jin D, Zhang Y, Yang C, Zhang Y, Kang X, Sun Y. The pathological mechanism of the COVID-19 convalescence and its treatment with traditional Chinese medicine. Front Pharmacol 2023; 13:1054312. [PMID: 36703736 PMCID: PMC9872123 DOI: 10.3389/fphar.2022.1054312] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2022] [Accepted: 12/16/2022] [Indexed: 01/12/2023] Open
Abstract
The severe acute respiratory syndrome coronavirus - 2 (SARS - CoV - 2) was reported to cause the Wuhan outbreak of the corona virus disease 2019(COVID-19). To date, the COVID-19 has infected more than 600 million people gloabally. As a growing number of patients recover from acute infections and are discharged from hospitals, the proportion of patients in the recovery period is gradually increasing. Many of these individuals have been reported to experience multiple symptoms during the convalescence, such as fatigue, dyspnea and pain which are designated as "long-COVID", "post-COVID syndrome" or "recovery sequelae. We searched for recent articles published in PubMed on COVID-19 convalescence and found that the pathogenesis of COVID-19 convalescence is not yet well recognized. It may be associated with incomplete recovery of immune system, parenchymal organ damage (liver or lung), coagulation abnormalities, "second hit" caused by viral infection, and Phenomenon of Cell Senescence-Associated Secretory Phenotype (SASP). Some drugs and psychological factors of patients also play a non-negligible role in it. We also found that the effect of traditional Chinese medicine (TCM) is effective in the treatment of the COVID-19 recovery phase, which can not only relieve the corresponding symptoms, but also improve the indicators and pulmonary fibrosis. Bufei Huoxue Capsule, as the only drug explicitly mentioned for COVID-19 recovery period, can exert strong rehabilitative effects on physiological activity in patients recovering from COVID-19. In addition, in previous studies, traditional Chinese medicine has been confirmed to have the ability to resist cytokine storms, as well as improve coagulation and myocardial damage, which makes it have potential therapeutic advantages in targeting the hyperimmune response, coagulation abnormalities and myocardial damage existing in the recovery period. In conclusion, the clinical symptoms of patients convalescing from COVID-19 are complex, and its pathogenesis has not been elucidated. traditional Chinese medicine, as a traditional treatment, its specific action and mechanism need to be confirmed by more studies, so that it can play a better role.
Collapse
Affiliation(s)
- Linlin Jiang
- Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China,Beijing University of Chinese Medicine, Beijing, China
| | - Xuedong An
- Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Yingying Duan
- Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China,Beijing University of Chinese Medicine, Beijing, China
| | - Fengmei Lian
- Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China,*Correspondence: Fengmei Lian,
| | - De Jin
- Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Yuehong Zhang
- Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Cunqing Yang
- Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Yuqing Zhang
- Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Xiaomin Kang
- Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China,Beijing University of Chinese Medicine, Beijing, China
| | - Yuting Sun
- Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| |
Collapse
|
112
|
Khreefa Z, Barbier MT, Koksal AR, Love G, Del Valle L. Pathogenesis and Mechanisms of SARS-CoV-2 Infection in the Intestine, Liver, and Pancreas. Cells 2023; 12:cells12020262. [PMID: 36672197 PMCID: PMC9856332 DOI: 10.3390/cells12020262] [Citation(s) in RCA: 12] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2022] [Revised: 12/30/2022] [Accepted: 01/05/2023] [Indexed: 01/11/2023] Open
Abstract
The novel coronavirus, SARS-CoV-2, rapidly spread worldwide, causing an ongoing global pandemic. While the respiratory system is the most common site of infection, a significant number of reported cases indicate gastrointestinal (GI) involvement. GI symptoms include anorexia, abdominal pain, nausea, vomiting, and diarrhea. Although the mechanisms of GI pathogenesis are still being examined, viral components isolated from stool samples of infected patients suggest a potential fecal-oral transmission route. In addition, viral RNA has been detected in blood samples of infected patients, making hematologic dissemination of the virus a proposed route for GI involvement. Angiotensin-converting enzyme 2 (ACE2) receptors serve as the cellular entry mechanism for the virus, and these receptors are particularly abundant throughout the GI tract, making the intestine, liver, and pancreas potential extrapulmonary sites for infection and reservoirs sites for developing mutations and new variants that contribute to the uncontrolled spread of the disease and resistance to treatments. This transmission mechanism and the dysregulation of the immune system play a significant role in the profound inflammatory and coagulative cascades that contribute to the increased severity and risk of death in several COVID-19 patients. This article reviews various potential mechanisms of gastrointestinal, liver, and pancreatic injury.
Collapse
Affiliation(s)
- Zaid Khreefa
- Department of Pathology, School of Medicine, Louisiana State University Health School of Medicine, New Orleans, LA 70112, USA
| | - Mallory T. Barbier
- Louisiana Cancer Research Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
| | - Ali Riza Koksal
- Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA
| | - Gordon Love
- Department of Pathology, School of Medicine, Louisiana State University Health School of Medicine, New Orleans, LA 70112, USA
| | - Luis Del Valle
- Department of Pathology, School of Medicine, Louisiana State University Health School of Medicine, New Orleans, LA 70112, USA
- Louisiana Cancer Research Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
- Correspondence:
| |
Collapse
|
113
|
Zsichla L, Müller V. Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors. Viruses 2023; 15:175. [PMID: 36680215 PMCID: PMC9863423 DOI: 10.3390/v15010175] [Citation(s) in RCA: 32] [Impact Index Per Article: 32.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Revised: 01/04/2023] [Accepted: 01/04/2023] [Indexed: 01/11/2023] Open
Abstract
The clinical course and outcome of COVID-19 are highly variable, ranging from asymptomatic infections to severe disease and death. Understanding the risk factors of severe COVID-19 is relevant both in the clinical setting and at the epidemiological level. Here, we provide an overview of host, viral and environmental factors that have been shown or (in some cases) hypothesized to be associated with severe clinical outcomes. The factors considered in detail include the age and frailty, genetic polymorphisms, biological sex (and pregnancy), co- and superinfections, non-communicable comorbidities, immunological history, microbiota, and lifestyle of the patient; viral genetic variation and infecting dose; socioeconomic factors; and air pollution. For each category, we compile (sometimes conflicting) evidence for the association of the factor with COVID-19 outcomes (including the strength of the effect) and outline possible action mechanisms. We also discuss the complex interactions between the various risk factors.
Collapse
Affiliation(s)
- Levente Zsichla
- Institute of Biology, Eötvös Loránd University, 1117 Budapest, Hungary
- National Laboratory for Health Security, Eötvös Loránd University, 1117 Budapest, Hungary
| | - Viktor Müller
- Institute of Biology, Eötvös Loránd University, 1117 Budapest, Hungary
- National Laboratory for Health Security, Eötvös Loránd University, 1117 Budapest, Hungary
| |
Collapse
|
114
|
Zanon M, Neri M, Pizzolitto S, Radaelli D, Concato M, Peruch M, D'Errico S. Liver pathology in COVID-19 related death and leading role of autopsy in the pandemic. World J Gastroenterol 2023; 29:200-220. [PMID: 36683722 PMCID: PMC9850946 DOI: 10.3748/wjg.v29.i1.200] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Revised: 11/14/2022] [Accepted: 12/21/2022] [Indexed: 01/04/2023] Open
Abstract
BACKGROUND Information on liver involvement in patients with coronavirus disease 2019 is currently fragmented.
AIM To highlight the pathological changes found during the autopsy of severe acute respiratory syndrome coronavirus 2 positive patients.
METHODS A systematic literature search on PubMed was carried out until June 21, 2022.
RESULTS A literature review reveals that pre-existing liver disease and elevation of liver enzyme in these patients are not common; liver enzyme elevations tend to be seen in those in critical conditions. Despite the poor expression of viral receptors in the liver, it seems that the virus is able to infect this organ and therefore cause liver damage. Unfortunately, to date, the search for the virus inside the liver is not frequent (16% of the cases) and only a small number show the presence of the virus. In most of the autopsy cases, macroscopic assessment is lacking, while microscopic evaluation of livers has revealed the frequent presence of congestion (42.7%) and steatosis (41.6%). Less frequent is the finding of hepatic inflammation or necrosis (19%) and portal inflammation (18%). The presence of microthrombi, frequently found in the lungs, is infrequent in the liver, with only 12% of cases presenting thrombotic formations within the vascular tree.
CONCLUSION To date, the greatest problem in interpreting these modifications remains the association of the damage with the direct action of the virus, rather than with the inflammation or alterations induced by hypoxia and hypovolemia in patients undergoing oxygen therapy and decompensated patients.
Collapse
Affiliation(s)
- Martina Zanon
- Department of Medical Surgical and Health Sciences, University of Trieste, Trieste 34149, Italy
| | - Margherita Neri
- Department of Medical Sciences, University of Ferrara, Ferrara 44121, Italy
| | - Stefano Pizzolitto
- Department of Pathology, Santa Maria della Misericordia University Hospital, Udine 33100, Italy
| | - Davide Radaelli
- Department of Medical Surgical and Health Sciences, University of Trieste, Trieste 34149, Italy
| | - Monica Concato
- Department of Medical Surgical and Health Sciences, University of Trieste, Trieste 34149, Italy
| | - Michela Peruch
- Department of Medical Surgical and Health Sciences, University of Trieste, Trieste 34149, Italy
| | - Stefano D'Errico
- Department of Medical Surgical and Health Sciences, University of Trieste, Trieste 34149, Italy
| |
Collapse
|
115
|
COVID-19: Has the Liver Been Spared? Int J Mol Sci 2023; 24:ijms24021091. [PMID: 36674607 PMCID: PMC9866733 DOI: 10.3390/ijms24021091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2022] [Revised: 01/03/2023] [Accepted: 01/04/2023] [Indexed: 01/09/2023] Open
Abstract
The liver is a secondary and often collateral target of COVID-19 disease but can lead to important consequences. COVID-19 might directly cause a high number of complications in patients with pre-existing chronic liver disease, increasing their risk of hepatic decompensation. Moreover, it also determines indirect consequences in the management of patients with liver disease, especially in those suffering from decompensated cirrhosis and HCC, as well as in the execution of their follow-up and the availability of all therapeutic possibilities. Liver imaging in COVID-19 patients proved to be highly nonspecific, but it can still be useful for identifying the complications that derive from the infection. Moreover, the recent implementation of telemedicine constitutes a possible solution to both the physical distancing and the re-organizational difficulties arising from the pandemic. The present review aims to encompass the currently hypothesized pathophysiological mechanisms of liver injury in patients with COVID-19 mediated by both the direct invasion of the virus and its indirect effects and analyze the consequence of the pandemic in patients with chronic liver disease and liver tumors, with particular regard to the management strategies that have been implemented to face this worldwide emergency and that can be further improved.
Collapse
|
116
|
Pathogenetic Mechanisms of Liver-Associated Injuries, Management, and Current Challenges in COVID-19 Patients. Biomolecules 2023; 13:biom13010099. [PMID: 36671484 PMCID: PMC9855873 DOI: 10.3390/biom13010099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2022] [Revised: 11/28/2022] [Accepted: 12/10/2022] [Indexed: 01/06/2023] Open
Abstract
The global outbreak of COVID-19 possesses serious challenges and adverse impacts for patients with progression of chronic liver disease and has become a major threat to public health. COVID-19 patients have a high risk of lung injury and multiorgan dysfunction that remains a major challenge to hepatology. COVID-19 patients and those with liver injury exhibit clinical manifestations, including elevation in ALT, AST, GGT, bilirubin, TNF-α, and IL-6 and reduction in the levels of CD4 and CD8. Liver injury in COVID-19 patients is induced through multiple factors, including a direct attack of SARS-CoV-2 on liver hepatocytes, hypoxia reperfusion dysfunction, cytokine release syndrome, drug-induced hepatotoxicity caused by lopinavir and ritonavir, immune-mediated inflammation, renin-angiotensin system, and coagulopathy. Cellular and molecular mechanisms underlying liver dysfunction are not fully understood in severe COVID-19 attacks. High mortality and the development of chronic liver diseases such as cirrhosis, alcoholic liver disease, autoimmune hepatitis, nonalcoholic fatty liver disease, and hepatocellular carcinoma are also associated with patients with liver damage. COVID-19 patients with preexisting or developing liver disease should be managed. They often need hospitalization and medication, especially in conjunction with liver transplants. In the present review, we highlight the attack of SARS-CoV-2 on liver hepatocytes by exploring the cellular and molecular events underlying the pathophysiological mechanisms in COVID-19 patients with liver injury. We also discuss the development of chronic liver diseases during the progression of SARS-CoV-2 replication. Lastly, we explore management principles in COVID-19 patients with liver injury and liver transplantation.
Collapse
|
117
|
Khan S, Alam S, Jain V, Kashyap V, Kapur P. Utility of hematological and biochemical parameters as a screening tool for assessing coronavirus disease 2019 infection and its severity. J Microsc Ultrastruct 2023. [DOI: 10.4103/jmau.jmau_59_22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
|
118
|
Ansari S, Kelbrick M, Paduret G, Diaz N, Menzel R, Rogers R, Wareham C, Griffiths C, Jugon S, Tidy K, Johnson S, Mann N, Tanner J, Millward T, Latif S. Clinical practice guideline for clozapine use in patients with
COVID
‐19. PROGRESS IN NEUROLOGY AND PSYCHIATRY 2023. [DOI: 10.1002/pnp.779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Affiliation(s)
- Saba Ansari
- Dr Ansari is a Specialty Registrar (ST5); Dr Kelbrick is a Consultant Psychiatrist; Dr Paduret is a Core Trainee Year 2; Ms Diaz is a Physical Health Advanced Nurse Practitioner; Ms Menzel is a Pharmacist; Ms Rowena Rogers is a Community Mental Health Nurse; Ms Wareham is a Community Mental Health Nurse; Dr Griffiths is a Senior Research and Evaluation Fellow; Ms Jugon is a EIP operations Manager; Ms Tidy is a CMHT Operations Manager; Ms Johnson is a Ward Matron; Dr Mann, Dr Tanner, Dr Millward, Dr
| | - Marlene Kelbrick
- Dr Ansari is a Specialty Registrar (ST5); Dr Kelbrick is a Consultant Psychiatrist; Dr Paduret is a Core Trainee Year 2; Ms Diaz is a Physical Health Advanced Nurse Practitioner; Ms Menzel is a Pharmacist; Ms Rowena Rogers is a Community Mental Health Nurse; Ms Wareham is a Community Mental Health Nurse; Dr Griffiths is a Senior Research and Evaluation Fellow; Ms Jugon is a EIP operations Manager; Ms Tidy is a CMHT Operations Manager; Ms Johnson is a Ward Matron; Dr Mann, Dr Tanner, Dr Millward, Dr
| | - Gabriela Paduret
- Dr Ansari is a Specialty Registrar (ST5); Dr Kelbrick is a Consultant Psychiatrist; Dr Paduret is a Core Trainee Year 2; Ms Diaz is a Physical Health Advanced Nurse Practitioner; Ms Menzel is a Pharmacist; Ms Rowena Rogers is a Community Mental Health Nurse; Ms Wareham is a Community Mental Health Nurse; Dr Griffiths is a Senior Research and Evaluation Fellow; Ms Jugon is a EIP operations Manager; Ms Tidy is a CMHT Operations Manager; Ms Johnson is a Ward Matron; Dr Mann, Dr Tanner, Dr Millward, Dr
| | - Natasha Diaz
- Dr Ansari is a Specialty Registrar (ST5); Dr Kelbrick is a Consultant Psychiatrist; Dr Paduret is a Core Trainee Year 2; Ms Diaz is a Physical Health Advanced Nurse Practitioner; Ms Menzel is a Pharmacist; Ms Rowena Rogers is a Community Mental Health Nurse; Ms Wareham is a Community Mental Health Nurse; Dr Griffiths is a Senior Research and Evaluation Fellow; Ms Jugon is a EIP operations Manager; Ms Tidy is a CMHT Operations Manager; Ms Johnson is a Ward Matron; Dr Mann, Dr Tanner, Dr Millward, Dr
| | - Rose Menzel
- Dr Ansari is a Specialty Registrar (ST5); Dr Kelbrick is a Consultant Psychiatrist; Dr Paduret is a Core Trainee Year 2; Ms Diaz is a Physical Health Advanced Nurse Practitioner; Ms Menzel is a Pharmacist; Ms Rowena Rogers is a Community Mental Health Nurse; Ms Wareham is a Community Mental Health Nurse; Dr Griffiths is a Senior Research and Evaluation Fellow; Ms Jugon is a EIP operations Manager; Ms Tidy is a CMHT Operations Manager; Ms Johnson is a Ward Matron; Dr Mann, Dr Tanner, Dr Millward, Dr
| | - Rowena Rogers
- Dr Ansari is a Specialty Registrar (ST5); Dr Kelbrick is a Consultant Psychiatrist; Dr Paduret is a Core Trainee Year 2; Ms Diaz is a Physical Health Advanced Nurse Practitioner; Ms Menzel is a Pharmacist; Ms Rowena Rogers is a Community Mental Health Nurse; Ms Wareham is a Community Mental Health Nurse; Dr Griffiths is a Senior Research and Evaluation Fellow; Ms Jugon is a EIP operations Manager; Ms Tidy is a CMHT Operations Manager; Ms Johnson is a Ward Matron; Dr Mann, Dr Tanner, Dr Millward, Dr
| | - Claire Wareham
- Dr Ansari is a Specialty Registrar (ST5); Dr Kelbrick is a Consultant Psychiatrist; Dr Paduret is a Core Trainee Year 2; Ms Diaz is a Physical Health Advanced Nurse Practitioner; Ms Menzel is a Pharmacist; Ms Rowena Rogers is a Community Mental Health Nurse; Ms Wareham is a Community Mental Health Nurse; Dr Griffiths is a Senior Research and Evaluation Fellow; Ms Jugon is a EIP operations Manager; Ms Tidy is a CMHT Operations Manager; Ms Johnson is a Ward Matron; Dr Mann, Dr Tanner, Dr Millward, Dr
| | - Chris Griffiths
- Dr Ansari is a Specialty Registrar (ST5); Dr Kelbrick is a Consultant Psychiatrist; Dr Paduret is a Core Trainee Year 2; Ms Diaz is a Physical Health Advanced Nurse Practitioner; Ms Menzel is a Pharmacist; Ms Rowena Rogers is a Community Mental Health Nurse; Ms Wareham is a Community Mental Health Nurse; Dr Griffiths is a Senior Research and Evaluation Fellow; Ms Jugon is a EIP operations Manager; Ms Tidy is a CMHT Operations Manager; Ms Johnson is a Ward Matron; Dr Mann, Dr Tanner, Dr Millward, Dr
| | - Sue Jugon
- Dr Ansari is a Specialty Registrar (ST5); Dr Kelbrick is a Consultant Psychiatrist; Dr Paduret is a Core Trainee Year 2; Ms Diaz is a Physical Health Advanced Nurse Practitioner; Ms Menzel is a Pharmacist; Ms Rowena Rogers is a Community Mental Health Nurse; Ms Wareham is a Community Mental Health Nurse; Dr Griffiths is a Senior Research and Evaluation Fellow; Ms Jugon is a EIP operations Manager; Ms Tidy is a CMHT Operations Manager; Ms Johnson is a Ward Matron; Dr Mann, Dr Tanner, Dr Millward, Dr
| | - Katy Tidy
- Dr Ansari is a Specialty Registrar (ST5); Dr Kelbrick is a Consultant Psychiatrist; Dr Paduret is a Core Trainee Year 2; Ms Diaz is a Physical Health Advanced Nurse Practitioner; Ms Menzel is a Pharmacist; Ms Rowena Rogers is a Community Mental Health Nurse; Ms Wareham is a Community Mental Health Nurse; Dr Griffiths is a Senior Research and Evaluation Fellow; Ms Jugon is a EIP operations Manager; Ms Tidy is a CMHT Operations Manager; Ms Johnson is a Ward Matron; Dr Mann, Dr Tanner, Dr Millward, Dr
| | - Sara Johnson
- Dr Ansari is a Specialty Registrar (ST5); Dr Kelbrick is a Consultant Psychiatrist; Dr Paduret is a Core Trainee Year 2; Ms Diaz is a Physical Health Advanced Nurse Practitioner; Ms Menzel is a Pharmacist; Ms Rowena Rogers is a Community Mental Health Nurse; Ms Wareham is a Community Mental Health Nurse; Dr Griffiths is a Senior Research and Evaluation Fellow; Ms Jugon is a EIP operations Manager; Ms Tidy is a CMHT Operations Manager; Ms Johnson is a Ward Matron; Dr Mann, Dr Tanner, Dr Millward, Dr
| | - Nick Mann
- Dr Ansari is a Specialty Registrar (ST5); Dr Kelbrick is a Consultant Psychiatrist; Dr Paduret is a Core Trainee Year 2; Ms Diaz is a Physical Health Advanced Nurse Practitioner; Ms Menzel is a Pharmacist; Ms Rowena Rogers is a Community Mental Health Nurse; Ms Wareham is a Community Mental Health Nurse; Dr Griffiths is a Senior Research and Evaluation Fellow; Ms Jugon is a EIP operations Manager; Ms Tidy is a CMHT Operations Manager; Ms Johnson is a Ward Matron; Dr Mann, Dr Tanner, Dr Millward, Dr
| | - James Tanner
- Dr Ansari is a Specialty Registrar (ST5); Dr Kelbrick is a Consultant Psychiatrist; Dr Paduret is a Core Trainee Year 2; Ms Diaz is a Physical Health Advanced Nurse Practitioner; Ms Menzel is a Pharmacist; Ms Rowena Rogers is a Community Mental Health Nurse; Ms Wareham is a Community Mental Health Nurse; Dr Griffiths is a Senior Research and Evaluation Fellow; Ms Jugon is a EIP operations Manager; Ms Tidy is a CMHT Operations Manager; Ms Johnson is a Ward Matron; Dr Mann, Dr Tanner, Dr Millward, Dr
| | - Tim Millward
- Dr Ansari is a Specialty Registrar (ST5); Dr Kelbrick is a Consultant Psychiatrist; Dr Paduret is a Core Trainee Year 2; Ms Diaz is a Physical Health Advanced Nurse Practitioner; Ms Menzel is a Pharmacist; Ms Rowena Rogers is a Community Mental Health Nurse; Ms Wareham is a Community Mental Health Nurse; Dr Griffiths is a Senior Research and Evaluation Fellow; Ms Jugon is a EIP operations Manager; Ms Tidy is a CMHT Operations Manager; Ms Johnson is a Ward Matron; Dr Mann, Dr Tanner, Dr Millward, Dr
| | - Shahid Latif
- Dr Ansari is a Specialty Registrar (ST5); Dr Kelbrick is a Consultant Psychiatrist; Dr Paduret is a Core Trainee Year 2; Ms Diaz is a Physical Health Advanced Nurse Practitioner; Ms Menzel is a Pharmacist; Ms Rowena Rogers is a Community Mental Health Nurse; Ms Wareham is a Community Mental Health Nurse; Dr Griffiths is a Senior Research and Evaluation Fellow; Ms Jugon is a EIP operations Manager; Ms Tidy is a CMHT Operations Manager; Ms Johnson is a Ward Matron; Dr Mann, Dr Tanner, Dr Millward, Dr
| |
Collapse
|
119
|
Miryan M, Moradi S, Soleimani D, Pasdar Y, Jangjoo A, Bagherniya M, Guest PC, Ashari S, Sahebkar A. The Potential Effect of Royal Jelly on Biomarkers Related to COVID-19 Infection and Severe Progression. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2023; 1412:443-455. [PMID: 37378782 DOI: 10.1007/978-3-031-28012-2_24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/29/2023]
Abstract
Royal jelly is a yellowish to white gel-like substance that is known as a "superfood" and consumed by queen bees. There are certain compounds in royal jelly considered to have health-promoting properties, including 10-hydroxy-2-decenoic acid and major royal jelly proteins. Royal jelly has beneficial effects on some disorders such as cardiovascular disease, dyslipidemia, multiple sclerosis, and diabetes. Antiviral, anti-inflammatory, antibacterial, antitumor, and immunomodulatory properties have been ascribed to this substance. This chapter describes the effects of royal jelly on COVID-19 disease.
Collapse
Affiliation(s)
- Mahsa Miryan
- Student Research Committee, Department of Nutritional Sciences, School of Nutritional Sciences and Food Technology, Kermanshah University of Medical Sciences, Kermanshah, Iran
- Research Center for Environmental Determinants of Health, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Shima Moradi
- Student Research Committee, Department of Nutritional Sciences, School of Nutritional Sciences and Food Technology, Kermanshah University of Medical Sciences, Kermanshah, Iran
- Research Center for Environmental Determinants of Health, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Davood Soleimani
- Department of Nutritional Sciences, School of Nutritional Sciences and Food Technology, Kermanshah University of Medical Sciences, Kermanshah, Iran
- Research Center of Oils and Fats, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Yahya Pasdar
- Research Center for Environmental Determinants of Health, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
- Department of Nutritional Sciences, School of Nutritional Sciences and Food Technology, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Ali Jangjoo
- Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
- Nutrition and Food Security Research Center and Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mohammad Bagherniya
- Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
- Nutrition and Food Security Research Center and Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Paul C Guest
- Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil
- Department of Psychiatry, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany
- Laboratory of Translational Psychiatry, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany
| | - Sorour Ashari
- Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Amirhossein Sahebkar
- Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
- Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
| |
Collapse
|
120
|
Kanda J, Wakasugi M, Kondo Y, Ueno S, Kaneko H, Okada Y, Okano Y, Kishihara Y, Hamaguchi J, Ishihara T, Igarashi Y, Nakae R, Miyamoto S, Yamada E, Ikechi D, Yamazaki M, Tanaka D, Sawada Y, Suda C, Yoshimura S, Onodera R, Kano K, Hongo T, Endo K, Iwasaki Y, Kodaira H, Yasuo S, Seki N, Okuda H, Nakajima S, Nagato T, Terazumi K, Nakamura S, Yokobori S. Heat stroke management during the COVID-19 pandemic: Recommendations from the experts in Japan (2nd edition). Acute Med Surg 2023; 10:e827. [PMID: 37056485 PMCID: PMC10086676 DOI: 10.1002/ams2.827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2023] [Accepted: 02/08/2023] [Indexed: 04/15/2023] Open
Abstract
Both coronavirus disease 2019 (COVID-19) and heat stroke have symptoms of fever or hyperthermia and the difficulty in distinguishing them could lead to a strain on emergency medical care. To mitigate the potential confusion that could arise from actions for preventing both COVID-19 spread and heat stroke, particularly in the context of record-breaking summer season temperatures, this work offers new knowledge and evidence that address concerns regarding indoor ventilation and indoor temperatures, mask wearing and heat stroke risk, and the isolation of older adults. Specifically, the current work is the second edition to the previously published guidance for handling heat stroke during the COVID-19 pandemic, prepared by the "Working group on heat stroke medical care during the COVID-19 epidemic," composed of members from four organizations in different medical and related fields. The group was established by the Japanese Association for Acute Medicine Heatstroke and Hypothermia Surveillance Committee. This second edition includes new knowledge, and conventional evidence gleaned from a primary selection of 60 articles from MEDLINE, one article from Cochrane, 13 articles from Ichushi, and a secondary/final selection of 56 articles. This work summarizes the contents that have been clarified in the prevention and treatment of infectious diseases and heat stroke to provide guidance for the prevention, diagnosis, and treatment of heat stroke during the COVID-19 pandemic.
Collapse
Affiliation(s)
- Jun Kanda
- Department of Emergency MedicineTeikyo University School of MedicineItabashiJapan
| | - Masahiro Wakasugi
- Department of Emergency and Disaster MedicineUniversity of ToyamaToyamaJapan
| | - Yutaka Kondo
- Department of Emergency and Critical Care MedicineJuntendo University Urayasu HospitalUrayasuJapan
| | - Satoru Ueno
- Japan Organisation of Occupational Health and SafetyNational Institute of Occupational Safety and HealthKiyoseJapan
| | - Hitoshi Kaneko
- Department of Trauma and Emergency MedicineTokyo Metropolitan Tama Medical CenterFuchuJapan
| | - Yohei Okada
- Department of Public Health Graduate School of MedicineKyoto UniversityKyotoJapan
| | - Yuichi Okano
- Department of Emergency MedicineKumamoto Sekijuji HospitalKumamotoJapan
| | - Yuki Kishihara
- Department of Urology, Emergency Room, Jichi Medical University Saitama Medical CenterJichi Medical UniversityShimotsukeJapan
| | - Jun Hamaguchi
- Department of Emergency and Critical Care MedicineTokyo Metropolitan Tama Medical CenterFuchuJapan
| | - Tadashi Ishihara
- Department of Emergency and Critical Care MedicineJuntendo University Urayasu HospitalUrayasuJapan
| | - Yutaka Igarashi
- Department of Emergency and Critical Care MedicineNippon Medical SchoolBunkyo CityJapan
| | - Ryuta Nakae
- Department of Emergency and Critical Care MedicineNippon Medical SchoolBunkyo CityJapan
| | - Sohma Miyamoto
- Department of Emergency and Critical Care MedicineSt. Luke's International HospitalChuo CityJapan
| | - Eri Yamada
- Advanced Medical Emergency Department and Critical Care CenterMaebashi Red Cross HospitalMaebashiJapan
| | - Daisuke Ikechi
- Department of Emergency and Critical Care MedicineHitachi General HospitalHitachiJapan
| | - Maiko Yamazaki
- Department of Emergency MedicineTeikyo University School of MedicineItabashiJapan
| | - Daiki Tanaka
- Department of Emergency MedicineTeikyo University School of MedicineItabashiJapan
| | - Yusuke Sawada
- Department of Emergency MedicineGunma University Graduate School of MedicineMaebashiJapan
| | - Chiaki Suda
- Department of Emergency and Critical Care MedicineSaku Central Hospital Advanced Care CenterSakuJapan
| | | | - Ryuta Onodera
- Department of Preventive ServicesKyoto University School of Public HealthKyotoJapan
| | - Kenichi Kano
- Emergency and Critical Care MedicineKokuritsu Byoin Kiko Kyoto Iryo CenterKyotoJapan
| | - Takashi Hongo
- Emergency DepartmentOkayama Saiseikai General HospitalOkayamaJapan
| | - Kaori Endo
- Orthopaedic Surgery, Sapporo Tokushukai HospitalHokkaido UniversitySapporoJapan
| | - Yohei Iwasaki
- Trauma and Acute Critical Care CenterTokyo Medical and Dental University HospitalTokyoJapan
| | | | | | - Nozomu Seki
- Department of Emergency and Critical Care MedicineJapanese Red Cross Saitama HospitalSaitamaJapan
| | - Hiroshi Okuda
- Division of Comprehensive MedicineTohoku University Graduate School of MedicineSendaiJapan
| | - Satoshi Nakajima
- Department of Emergency MedicineKyoto Prefectural University of MedicineKyotoJapan
| | - Tadashi Nagato
- Department of Respiratory MedicineJCHO Tokyo Yamate Medical CenterKyotoJapan
| | - Keiko Terazumi
- Trauma and Critical CareJapanese Red Cross Kumamoto HospitalKumamotoJapan
| | - Satoshi Nakamura
- Department of Emergency MedicineAsahi General HospitalAsahiJapan
| | - Shoji Yokobori
- Department of Emergency and Critical Care MedicineNippon Medical SchoolBunkyo CityJapan
| |
Collapse
|
121
|
Jhajra S, Sharma A, Diwakar K, Gupta BK, Tanti SK. Acute hepatitis with non-alcoholic fatty liver disease-expanding clinical spectrum in COVID-19 exposed children: case report and review of literature. Sudan J Paediatr 2023; 23:91-97. [PMID: 37663107 PMCID: PMC10468639 DOI: 10.24911/sjp.106-1636877693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2021] [Accepted: 04/09/2022] [Indexed: 09/05/2023]
Abstract
Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can adversely affect extra-pulmonary organs, such as the liver, heart and gastrointestinal tract apart from lungs. Although studies are showing that serum glutamic-oxaloacetic transaminase and serum glutamic-pyruvic transaminase are mildly elevated along with serum bilirubin in adult patients with mild to severe cases of COVID-19 disease, data are limited regarding liver injury in children infected with COVID virus. We report the case of a 9-year-old female patient who developed signs and symptoms of upper respiratory tract infection due to COVID-19 virus infection and subsequently developed fatty liver disease on follow-up. To our knowledge, this is the second case report in children showing an association between non-alcoholic fatty liver disease and SARS-CoV-2 virus infection.
Collapse
Affiliation(s)
- Sandeep Jhajra
- Department of Paediatrics, Tata Main Hospital, Jamshedpur, India
| | - Akshada Sharma
- Department of Paediatrics, Post Graduate Institute of Medical Sciences, Rohtak, India
| | - Kumar Diwakar
- Department of Paediatrics, Tata Main Hospital, Jamshedpur, India
| | | | | |
Collapse
|
122
|
Muacevic A, Adler JR, Leu S, Bogdan MA. Complications During Hospitalization in Patients With SARS-CoV-2 Pneumonia in a Romanian Pulmonary Center. Cureus 2023; 15:e33882. [PMID: 36819389 PMCID: PMC9934938 DOI: 10.7759/cureus.33882] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/17/2023] [Indexed: 01/19/2023] Open
Abstract
Introduction The coronavirus disease (COVID-19) was declared a pandemic by the World Health Organization (WHO) on March 11, 2020. Facing a new and unknown virus, the entire medical community made considerable efforts to find a specific treatment, develop guidelines, and even create a vaccine. Besides all the measures taken, a wide range of complications associated with the disease increased the mortality and morbidity rates, adding more difficulty to the management of the patients. Study design We performed a retrospective study, including the patients with SARS-CoV-2 pneumonia who were admitted to our hospital between March 2020 and August 2021. We analyzed complications that developed during the hospitalization, such as respiratory failure or acute injury to other organs (the heart, pancreas, kidneys, and liver), and whether they were treatment- and hospitalization-related. Results One thousand eight hundred and forty-four cases were evaluated, and we analyzed the complications that developed during the hospitalization. Out of this, 1392 (75.48%) cases developed at least one complication during hospitalization, most frequently respiratory failure (71.14%), hyperglycemia (43.54%), renal injury (42.67%), or cardiovascular events (7.10%). Conclusion SARS-CoV-2 infection in hospitalized patients with pneumonia can cause injuries to any organ, making the management of those patients even more difficult.
Collapse
|
123
|
Picon Y, Joveleviths D, Alvares-DA-Silva MR. MINIMAL LIVER ENZYMES ABNORMALITIES AT ADMISSION ARE RELATED TO SEVERE COVID-19 CLINICAL COURSE IN A LARGE BRAZILIAN COHORT. ARQUIVOS DE GASTROENTEROLOGIA 2023; 60:11-20. [PMID: 37194770 DOI: 10.1590/s0004-2803.202301000-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Accepted: 12/08/2022] [Indexed: 05/18/2023]
Abstract
BACKGROUND COVID-19 is a multisystemic disease, primarily affecting the respiratory system. Liver involvement is frequent, but the impact on the clinical course and outcomes are controversial. OBJECTIVE The aim was to assess liver function at the admission and evaluate its effects on severity and mortality in hospitalized patients with COVID-19. METHODS This is a retrospective study of hospitalized patients in a tertiary hospital in Brazil, with a PCR-confirmed SARS-CoV-2 infection between April and October 2020. 1080 out of 1229 patients had liver enzymes on admission and were divided in two cohorts, based on the presence or absence of abnormal liver enzymes (ALE). Demographic, clinical, laboratory, imaging, clinical severity, and mortality were evaluated. Patients were followed until discharge, death or transfer to another institution. RESULTS Median age was 60 years and 51.5% were male. The more frequent comorbidities were hypertension (51.2%), and diabetes (31.6%). Chronic liver disease and cirrhosis were present in 8.6% and 2.3%, respectively. ALE (aminotransferases higher than 40 IU/L) were present in 56.9% of patients [mild (1-2 times): 63.9%; moderate (2-5 times): 29.8%; severe (>5 times): 6.3%]. Male gender [RR 1.49, P=0.007], increased total bilirubin [RR 1.18, P<0.001] and chronic liver disease [RR 1.47, P=0.015] were predictors of abnormal aminotransferases on admission. Patients with ALE had a higher risk of disease severity [RR 1.19; P=0.004]. There was no association among ALE and mortality. CONCLUSION ALE is common in COVID-19 hospitalized patients and were independently correlated with severe COVID-19. Even mild ALE at admission may be a severity prognostic marker.
Collapse
Affiliation(s)
- Ysela Picon
- Hospital de Clínicas de Porto Alegre, Serviço de Gastroenterologia, Porto Alegre, RS, Brasil
- Organização Mundial de Gastroenterologia, WGO Porto Alegre Hepatology Training Center, Porto Alegre, RS, Brasil
- Universidade Federal do Rio Grande do Sul, Faculdade de Medicina, Programa de Pós-Graduação Ciências em Gastroenterologia e Hepatologia, Porto Alegre, RS, Brasil
| | - Dvora Joveleviths
- Universidade Federal do Rio Grande do Sul, Faculdade de Medicina, Programa de Pós-Graduação Ciências em Gastroenterologia e Hepatologia, Porto Alegre, RS, Brasil
| | - Mario Reis Alvares-DA-Silva
- Hospital de Clínicas de Porto Alegre, Serviço de Gastroenterologia, Porto Alegre, RS, Brasil
- Organização Mundial de Gastroenterologia, WGO Porto Alegre Hepatology Training Center, Porto Alegre, RS, Brasil
- Universidade Federal do Rio Grande do Sul, Faculdade de Medicina, Programa de Pós-Graduação Ciências em Gastroenterologia e Hepatologia, Porto Alegre, RS, Brasil
- Pesquisador CNPq
| |
Collapse
|
124
|
Dong X, Zeng DY, Xing QQ, Hong MZ, Pan JS. Liver chemistries in severe or non-severe cases of COVID-19: A systematic review and meta-analysis. World J Hepatol 2022; 14:2012-2024. [PMID: 36618330 PMCID: PMC9813841 DOI: 10.4254/wjh.v14.i12.2012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/03/2022] [Revised: 10/21/2022] [Accepted: 12/21/2022] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND Coronavirus disease (COVID-19) patients exhibit different patterns of liver impairment, according to growing evidence.
AIM In this study, we sought to provide a comprehensive analysis of liver test parameters in patients with severe and non-severe COVID-19.
METHODS We performed a meta-analysis of published liver manifestations and described the liver damage in COVID-19. We searched PubMed, Google Scholar, Embase, Cochrane Library, medRxiv, bioRxiv, and three Chinese electronic databases through April 18, 2020, in accordance with the Preferred Reporting Items for Meta-Analyses. We analyzed pooled data on liver chemistries stratified by COVID-19 severity using a fixed or random-effects model.
RESULTS A meta-analysis of 56 studies, including 11052 patients, found that the pooled mean alanine aminotransferase (ALT) in severe COVID-19 cases was 35.9 IU/L whereas in non-severe COVID-19 cases was 27.3 IU/L. Average aspartate aminotransferase (AST) levels were 44.3 IU/L in severe cases compared to 27.9 IU/L in non-severe cases. In addition, AST levels are often higher than ALT levels regardless of disease severity. The severe cases tended to have a higher gamma-glutamyltransferase level but a lower albumin level than the non-severe cases.
CONCLUSION Severe COVID-19 was more likely to be associated with abnormal liver test results. Monitoring liver chemistry closely can help detect disease progression early.
Collapse
Affiliation(s)
- Xuan Dong
- Department of Hepatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, Fujian Province, China
| | - Dan-Yi Zeng
- Department of Hepatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, Fujian Province, China
| | - Qing-Qing Xing
- Department of Hepatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, Fujian Province, China
| | - Mei-Zhu Hong
- Department of Traditional Chinese Medicine, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350005, Fujian Province, China
| | - Jin-Shui Pan
- Department of Hepatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, Fujian Province, China
| |
Collapse
|
125
|
Maev IV, Osadchuk MA. Liver disease during the pandemic of COVID-19 infection: prediction of the course and tactics of management: A review. TERAPEVT ARKH 2022; 94:1326-1332. [PMID: 37167173 DOI: 10.26442/00403660.2022.11.201934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2022] [Accepted: 12/26/2022] [Indexed: 12/27/2022]
Abstract
The hepatic consequences of SARS-CoV-2 infection are now recognized as an important component of CoronaVIrus Disease 2019 (COVID-19). This aspect is most clinically relevant in patients with pre-existing chronic liver disease (CKD), who are at extremely high risk of severe COVID-19 and death. Risk factors for severe CKD, especially in people with liver cirrhosis and non-alcoholic fatty liver disease, are the direct and indirect cytotoxic effects of coronavirus against the background of systemic inflammation, blood clotting disorders and immune dysfunction. The severe negative impact of the pandemic in the presence of CKD and the difficulties of patient relationships contribute to the progressive increase in the global burden of liver disease on the health system.
Collapse
|
126
|
De Novo Autoimmune Hepatitis after COVID-19 Infection in an Unvaccinated Patient. Case Reports Hepatol 2022; 2022:8409269. [PMID: 36590671 PMCID: PMC9800079 DOI: 10.1155/2022/8409269] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Revised: 10/03/2022] [Accepted: 11/12/2022] [Indexed: 12/24/2022] Open
Abstract
Liver test abnormalities have been described during severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection causing coronavirus disease 2019. Most of them consist of elevation of the aminotransferases that resolve once the infection subsides. There are several reports of autoimmune hepatitis developing after vaccination against COVID-19 and one case of autoimmune hepatitis following COVID-19 infection. We present a patient that was not vaccinated against COVID-19 and developed resistant de novo autoimmune hepatitis following COVID-19 infection requiring aggressive immunosuppression.
Collapse
|
127
|
Hu WS, Jiang FY, Shu W, Zhao R, Cao JM, Wang DP. Liver injury in COVID-19: A minireview. World J Gastroenterol 2022; 28:6716-6731. [PMID: 36620342 PMCID: PMC9813934 DOI: 10.3748/wjg.v28.i47.6716] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/12/2022] [Revised: 11/02/2022] [Accepted: 11/23/2022] [Indexed: 12/19/2022] Open
Abstract
Coronavirus disease 2019 (COVID-19), caused by infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has escalated into a global tragedy afflicting human health, life, and social governance. Through the increasing depth of research and a better understanding of this disease, it has been ascertained that, in addition to the lungs, SARS-CoV-2 can also induce injuries to other organs including the liver. Liver injury is a common clinical manifestation of COVID-19, particularly in severe cases, and is often associated with a poorer prognosis and higher severity of COVID-19. This review focuses on the general existing information on liver injury caused by COVID-19, including risk factors and subpopulations of liver injury in COVID-19, the association between preexisting liver diseases and the severity of COVID-19, and the potential mechanisms by which SARS-CoV-2 affects the liver. This review may provide some useful information for the development of therapeutic and preventive strategies for COVID-19-associated liver injury.
Collapse
Affiliation(s)
- Wen-Shu Hu
- Key Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
- Department of Physiology, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
| | - Fang-Ying Jiang
- Key Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
- Department of Physiology, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
| | - Wen Shu
- Key Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
- Department of Physiology, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
| | - Rong Zhao
- Key Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
- Department of Physiology, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
| | - Ji-Min Cao
- Key Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
- Department of Physiology, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
| | - De-Ping Wang
- Department of Physiology, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
| |
Collapse
|
128
|
Polyzogopoulou E, Amoiridou P, Abraham TP, Ventoulis I. Acute liver injury in COVID-19 patients hospitalized in the intensive care unit: Narrative review. World J Gastroenterol 2022; 28:6662-6688. [PMID: 36620339 PMCID: PMC9813941 DOI: 10.3748/wjg.v28.i47.6662] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Revised: 11/14/2022] [Accepted: 12/05/2022] [Indexed: 12/19/2022] Open
Abstract
In recent years, humanity has been confronted with a global pandemic due to coronavirus disease 2019 (COVID-19), which has caused an unprecedented health and economic crisis worldwide. Apart from the respiratory symptoms, which are considered the principal manifestations of COVID-19, it has been recognized that COVID-19 constitutes a systemic inflammatory process affecting multiple organ systems. Across the spectrum of organ involvement in COVID-19, acute liver injury (ALI) has been gradually gaining increasing attention by the international scientific community. COVID-19 associated liver impairment can affect a considerable proportion of COVID-19 patients and seems to correlate with the severity of the disease course. Indeed, COVID-19 patients hospitalized in the intensive care unit (ICU) run a greater risk of developing ALI due to the severity of their clinical condition and in the context of multi-organ failure. The putative pathophysiological mechanisms of COVID-19 induced ALI in ICU patients remain poorly understood and appear to be multifactorial in nature. Several theories have been proposed to explain the occurrence of ALI in the ICU setting, such as hypoperfusion and ischemia due to hemodynamic instability, passive liver congestion as a result of congestive heart failure, ischemia-reperfusion injury, hypoxia due to respiratory failure, mechanical ventilation itself, sepsis and septic shock, cytokine storm, endotheliitis with concomitant coagulopathy, drug-induced liver injury, parenteral nutrition and direct cytopathic viral effect. It should be noted that no specific therapy for COVID-19 induced ALI exists. Therefore, the therapeutic approach lies in preventive measures and is exclusively supportive once ALI ensues. The aim of the current review is to scrutinize the existing evidence on COVID-19 associated ALI in ICU patients, explore its clinical implications, shed light on the underlying pathophysiological mechanisms and propose potential therapeutic approaches. Ongoing research on the particular scientific field will further elucidate the pathophysiology behind ALI and address unresolved issues, in the hope of mitigating the tremendous health consequences imposed by COVID-19 on ICU patients.
Collapse
Affiliation(s)
- Effie Polyzogopoulou
- Department of Emergency Medicine, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens 12462, Greece
| | - Pinelopi Amoiridou
- Department of Intensive Care, AHEPA University Hospital, Thessaloniki 54621, Greece
| | - Theodore P Abraham
- Hypertrophic Cardiomyopathy Center of Excellence, University of California, San Francisco, CA 94117, United States
| | - Ioannis Ventoulis
- Department of Occupational Therapy, University of Western Macedonia, Ptolemaida 50200, Greece
| |
Collapse
|
129
|
Choaib A, Issa E, El Choueiry F, Eldin JN, Shbaklo K, Alhajj M, Sawaya RT, Assi G, Nader M, Chatila R, Faour WH. SARS-CoV-2-mediated liver injury: pathophysiology and mechanisms of disease. Inflamm Res 2022; 72:301-312. [PMID: 36539655 PMCID: PMC9767399 DOI: 10.1007/s00011-022-01683-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2022] [Revised: 12/13/2022] [Accepted: 12/16/2022] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND SARS-CoV-2-induced severe inflammatory response can be associated with severe medical consequences leading to multi-organ failure, including the liver. The main mechanism behind this assault is the aggressive cytokine storm that induces cytotoxicity in various organs. Of interest, hepatic stellate cells (HSC) respond acutely to liver injury through several molecular mechanisms, hence furthering the perpetuation of the cytokine storm and its resultant tissue damage. In addition, hepatocytes undergo apoptosis or necrosis resulting in the release of pro-inflammatory and pro-fibrogenic mediators that lead to chronic liver inflammation. AIMS The aim of this review is to summarize available data on SARS-CoV-2-induced liver inflammation in addition to evaluate the potential effect of anti-inflammatory drugs in attenuating SARS-CoV-2-induced liver inflammation. METHODS Thorough PubMed search was done to gather and summarize published data on SARS-CoV-2-induced liver inflammation. Additionally, various anti-inflammatory potential treatments were also documented. RESULTS Published data documented SARS-CoV-2 infection of liver tissues and is prominent in most liver cells. Also, histological analysis showed various features of tissues damage, e.g., hepatocellular necrosis, mitosis, cellular infiltration, and fatty degeneration in addition to microvesicular steatosis and inflammation. Finally, the efficacy of the different drugs used to treat SARS-CoV-2-induced liver injury, in particular the anti-inflammatory remedies, are likely to have some beneficial effect to treat liver injury in COVID-19. CONCLUSION SARS-CoV-2-induced liver inflammation is a serious condition, and drugs with potent anti-inflammatory effect can play a major role in preventing irreversible liver damage in COVID-19.
Collapse
Affiliation(s)
- Ali Choaib
- Gilbert & Rose-Marie Chagoury School of Medicine, Lebanese American University, P.O. Box 36, Byblos, Lebanon
| | - Elio Issa
- Gilbert & Rose-Marie Chagoury School of Medicine, Lebanese American University, P.O. Box 36, Byblos, Lebanon
| | - Francesca El Choueiry
- Gilbert & Rose-Marie Chagoury School of Medicine, Lebanese American University, P.O. Box 36, Byblos, Lebanon
| | - Jade Nasser Eldin
- Gilbert & Rose-Marie Chagoury School of Medicine, Lebanese American University, P.O. Box 36, Byblos, Lebanon
| | - Khodor Shbaklo
- Gilbert & Rose-Marie Chagoury School of Medicine, Lebanese American University, P.O. Box 36, Byblos, Lebanon
| | - Maryline Alhajj
- Gilbert & Rose-Marie Chagoury School of Medicine, Lebanese American University, P.O. Box 36, Byblos, Lebanon
| | - Ramy Touma Sawaya
- Gilbert & Rose-Marie Chagoury School of Medicine, Lebanese American University, P.O. Box 36, Byblos, Lebanon
| | - Ghaith Assi
- Gilbert & Rose-Marie Chagoury School of Medicine, Lebanese American University, P.O. Box 36, Byblos, Lebanon
| | - Moni Nader
- Department of Physiology and Immunology, College of Medicine and Health Sciences, Khalifa University of Science and Technology, P.O. Box 127788, Abu Dhabi, United Arab Emirates
- Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
| | - Rajaa Chatila
- Gilbert & Rose-Marie Chagoury School of Medicine, Lebanese American University, P.O. Box 36, Byblos, Lebanon
- Internal Medicine-Gastroenterology, Lebanese American University Medical Center-Rizk Hospital (LAUMC-RH), Beirut, Lebanon
| | - Wissam H Faour
- Gilbert & Rose-Marie Chagoury School of Medicine, Lebanese American University, P.O. Box 36, Byblos, Lebanon.
| |
Collapse
|
130
|
Rössler T, Berezhnoy G, Singh Y, Cannet C, Reinsperger T, Schäfer H, Spraul M, Kneilling M, Merle U, Trautwein C. Quantitative Serum NMR Spectroscopy Stratifies COVID-19 Patients and Sheds Light on Interfaces of Host Metabolism and the Immune Response with Cytokines and Clinical Parameters. Metabolites 2022; 12:metabo12121277. [PMID: 36557315 PMCID: PMC9781847 DOI: 10.3390/metabo12121277] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2022] [Revised: 12/08/2022] [Accepted: 12/13/2022] [Indexed: 12/23/2022] Open
Abstract
The complex manifestations of COVID-19 are still not fully decoded on the molecular level. We combined quantitative the nuclear magnetic resonance (NMR) spectroscopy serum analysis of metabolites, lipoproteins and inflammation markers with clinical parameters and a targeted cytokine panel to characterize COVID-19 in a large (534 patient samples, 305 controls) outpatient cohort of recently tested PCR-positive patients. The COVID-19 cohort consisted of patients who were predominantly in the initial phase of the disease and mostly exhibited a milder disease course. Concerning the metabolic profiles of SARS-CoV-2-infected patients, we identified markers of oxidative stress and a severe dysregulation of energy metabolism. NMR markers, such as phenylalanine, inflammatory glycoproteins (Glyc) and their ratio with the previously reported supramolecular phospholipid composite (Glyc/SPC), showed a predictive power comparable to laboratory parameters such as C-reactive protein (CRP) or ferritin. We demonstrated interfaces between the metabolism and the immune system, e.g., we could trace an interleukin (IL-6)-induced transformation of a high-density lipoprotein (HDL) to a pro-inflammatory actor. Finally, we showed that metadata such as age, sex and constitution (e.g., body mass index, BMI) need to be considered when exploring new biomarkers and that adding NMR parameters to existing diagnoses expands the diagnostic toolbox for patient stratification and personalized medicine.
Collapse
Affiliation(s)
- Titus Rössler
- Werner Siemens Imaging Center, Department for Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen, 72076 Tübingen, Germany
| | - Georgy Berezhnoy
- Werner Siemens Imaging Center, Department for Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen, 72076 Tübingen, Germany
| | - Yogesh Singh
- Institute of Medical Genetics & Applied Genomics, University Hospital Tübingen, 72076 Tübingen, Germany
| | - Claire Cannet
- Bruker BioSpin GmbH, Applied Industrial and Clinical Division, 76275 Ettlingen, Germany
| | - Tony Reinsperger
- Bruker BioSpin GmbH, Applied Industrial and Clinical Division, 76275 Ettlingen, Germany
| | - Hartmut Schäfer
- Bruker BioSpin GmbH, Applied Industrial and Clinical Division, 76275 Ettlingen, Germany
| | - Manfred Spraul
- Bruker BioSpin GmbH, Applied Industrial and Clinical Division, 76275 Ettlingen, Germany
| | - Manfred Kneilling
- Werner Siemens Imaging Center, Department for Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen, 72076 Tübingen, Germany
- Department of Dermatology, Eberhard Karls University Tübingen, 72076 Tübingen, Germany
- Cluster of Excellence iFIT (EXC 2180) “Image-guided and Functionally Instructed Tumor Therapies”, Medical Faculty, Eberhard Karls University Tübingen, 72076 Tübingen, Germany
| | - Uta Merle
- Department of Internal Medicine IV, University Hospital Heidelberg, 69120 Heidelberg, Germany
| | - Christoph Trautwein
- Werner Siemens Imaging Center, Department for Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen, 72076 Tübingen, Germany
- Correspondence:
| |
Collapse
|
131
|
De Simone B, Abu-Zidan FM, Chouillard E, Di Saverio S, Sartelli M, Podda M, Gomes CA, Moore EE, Moug SJ, Ansaloni L, Kluger Y, Coccolini F, Landaluce-Olavarria A, Estraviz-Mateos B, Uriguen-Etxeberria A, Giordano A, Luna AP, Amín LAH, Hernández AMP, Shabana A, Dzulkarnaen ZA, Othman MA, Sani MI, Balla A, Scaramuzzo R, Lepiane P, Bottari A, Staderini F, Cianchi F, Cavallaro A, Zanghì A, Cappellani A, Campagnacci R, Maurizi A, Martinotti M, Ruggieri A, Jusoh AC, Rahman KA, Zulkifli ASM, Petronio B, Matías-García B, Quiroga-Valcárcel A, Mendoza-Moreno F, Atanasov B, Campanile FC, Vecchioni I, Cardinali L, Travaglini G, Sebastiani E, Chooklin S, Chuklin S, Cianci P, Restini E, Capuzzolo S, Currò G, Filippo R, Rispoli M, Aparicio-Sánchez D, Muñóz-Cruzado VD, Barbeito SD, Delibegovic S, Kesetovic A, Sasia D, Borghi F, Giraudo G, Visconti D, Doria E, Santarelli M, Luppi D, Bonilauri S, Grossi U, Zanus G, Sartori A, Piatto G, De Luca M, Vita D, Conti L, Capelli P, Cattaneo GM, Marinis A, Vederaki SA, Bayrak M, Altıntas Y, Uzunoglu MY, Demirbas IE, Altinel Y, Meric S, Aktimur YE, Uymaz DS, Omarov N, Azamat I, Lostoridis E, Nagorni EA, Pujante A, Anania G, Bombardini C, Bagolini F, Gonullu E, Mantoglu B, Capoglu R, Cappato S, Muzio E, Colak E, Polat S, Koylu ZA, Altintoprak F, Bayhan Z, Akin E, Andolfi E, Rezart S, Kim JI, Jung SW, Shin YC, Enciu O, Toma EA, Medas F, Canu GL, Cappellacci F, D’Acapito F, Ercolani G, Solaini L, Roscio F, Clerici F, Gelmini R, Serra F, Rossi EG, Fleres F, Clarizia G, Spolini A, Ferrara F, Nita G, Sarnari J, Gachabayov M, Abdullaev A, Poillucci G, Palini GM, Veneroni S, Garulli G, Piccoli M, Pattacini GC, Pecchini F, Argenio G, Armellino MF, Brisinda G, Tedesco S, Fransvea P, Ietto G, Franchi C, Carcano G, Martines G, Trigiante G, Negro G, Vega GM, González AR, Ojeda L, Piccolo G, Bondurri A, Maffioli A, Guerci C, Sin BH, Zuhdi Z, Azman A, Mousa H, al Bahri S, Augustin G, Romic I, Moric T, Nikolopoulos I, Andreuccetti J, Pignata G, D’Alessio R, Kenig J, Skorus U, Fraga GP, Hirano ES, de Lima Bertuol JV, Isik A, Kurnaz E, Asghar MS, Afzal A, Akbar A, Nikolouzakis TK, Lasithiotakis K, Chrysos E, Das K, Özer N, Seker A, Ibrahim M, Hamid HKS, Babiker A, Bouliaris K, Koukoulis G, Kolla CC, Lucchi A, Agostinelli L, Taddei A, Fortuna L, Agostini C, Licari L, Viola S, Callari C, Laface L, Abate E, Casati M, Anastasi A, Canonico G, Gabellini L, Tosi L, Guariniello A, Zanzi F, Bains L, Sydorchuk L, Iftoda O, Sydorchuk A, Malerba M, Costanzo F, Galleano R, Monteleone M, Costanzi A, Riva C, Walędziak M, Kwiatkowski A, Czyżykowski Ł, Major P, Strzałka M, Matyja M, Natkaniec M, Valenti MR, Di Vita MDP, Sotiropoulou M, Kapiris S, Massalou D, Veroux M, Volpicelli A, Gioco R, Uccelli M, Bonaldi M, Olmi S, Nardi M, Livadoti G, Mesina C, Dumitrescu TV, Ciorbagiu MC, Ammendola M, Ammerata G, Romano R, Slavchev M, Misiakos EP, Pikoulis E, Papaconstantinou D, Elbahnasawy M, Abdel-elsalam S, Felsenreich DM, Jedamzik J, Michalopoulos NV, Sidiropoulos TA, Papadoliopoulou M, Cillara N, Deserra A, Cannavera A, Negoi I, Schizas D, Syllaios A, Vagios I, Gourgiotis S, Dai N, Gurung R, Norrey M, Pesce A, Feo CV, Fabbri N, Machairas N, Dorovinis P, Keramida MD, Mulita F, Verras GI, Vailas M, Yalkin O, Iflazoglu N, Yigit D, Baraket O, Ayed K, Ghalloussi MH, Patias P, Ntokos G, Rahim R, Bala M, Kedar A, Sawyer RG, Trinh A, Miller K, Sydorchuk R, Knut R, Plehutsa O, Liman RK, Ozkan Z, Kader SA, Gupta S, Gureh M, Saeidi S, Aliakbarian M, Dalili A, Shoko T, Kojima M, Nakamoto R, Atici SD, Tuncer GK, Kaya T, Delis SG, Rossi S, Picardi B, del Monte SR, Triantafyllou T, Theodorou D, Pintar T, Salobir J, Manatakis DK, Tasis N, Acheimastos V, Ioannidis O, Loutzidou L, Symeonidis S, de Sá TC, Rocha M, Guagni T, Pantalone D, Maltinti G, Khokha V, Abdel-elsalam W, Ghoneim B, López-Ruiz JA, Kara Y, Zainudin S, Hayati F, Azizan N, Khei VTP, Yi RCX, Sellappan H, Demetrashvili Z, Lekiashvili N, Tvaladze A, Froiio C, Bernardi D, Bonavina L, Gil-Olarte A, Grassia S, Romero-Vargas E, Bianco F, Gumbs AA, Dogjani A, Agresta F, Litvin A, Balogh ZJ, Gendrikson G, Martino C, Damaskos D, Pararas N, Kirkpatrick A, Kurtenkov M, Gomes FC, Pisanu A, Nardello O, Gambarini F, Aref H, Angelis ND, Agnoletti V, Biondi A, Vacante M, Griggio G, Tutino R, Massani M, Bisetto G, Occhionorelli S, Andreotti D, Lacavalla D, Biffl WL, Catena F. The ChoCO-W prospective observational global study: Does COVID-19 increase gangrenous cholecystitis? World J Emerg Surg 2022; 17:61. [PMID: 36527038 PMCID: PMC9755784 DOI: 10.1186/s13017-022-00466-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2022] [Accepted: 10/15/2022] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND The incidence of the highly morbid and potentially lethal gangrenous cholecystitis was reportedly increased during the COVID-19 pandemic. The aim of the ChoCO-W study was to compare the clinical findings and outcomes of acute cholecystitis in patients who had COVID-19 disease with those who did not. METHODS Data were prospectively collected over 6 months (October 1, 2020, to April 30, 2021) with 1-month follow-up. In October 2020, Delta variant of SARS CoV-2 was isolated for the first time. Demographic and clinical data were analyzed and reported according to the STROBE guidelines. Baseline characteristics and clinical outcomes of patients who had COVID-19 were compared with those who did not. RESULTS A total of 2893 patients, from 42 countries, 218 centers, involved, with a median age of 61.3 (SD: 17.39) years were prospectively enrolled in this study; 1481 (51%) patients were males. One hundred and eighty (6.9%) patients were COVID-19 positive, while 2412 (93.1%) were negative. Concomitant preexisting diseases including cardiovascular diseases (p < 0.0001), diabetes (p < 0.0001), and severe chronic obstructive airway disease (p = 0.005) were significantly more frequent in the COVID-19 group. Markers of sepsis severity including ARDS (p < 0.0001), PIPAS score (p < 0.0001), WSES sepsis score (p < 0.0001), qSOFA (p < 0.0001), and Tokyo classification of severity of acute cholecystitis (p < 0.0001) were significantly higher in the COVID-19 group. The COVID-19 group had significantly higher postoperative complications (32.2% compared with 11.7%, p < 0.0001), longer mean hospital stay (13.21 compared with 6.51 days, p < 0.0001), and mortality rate (13.4% compared with 1.7%, p < 0.0001). The incidence of gangrenous cholecystitis was doubled in the COVID-19 group (40.7% compared with 22.3%). The mean wall thickness of the gallbladder was significantly higher in the COVID-19 group [6.32 (SD: 2.44) mm compared with 5.4 (SD: 3.45) mm; p < 0.0001]. CONCLUSIONS The incidence of gangrenous cholecystitis is higher in COVID patients compared with non-COVID patients admitted to the emergency department with acute cholecystitis. Gangrenous cholecystitis in COVID patients is associated with high-grade Clavien-Dindo postoperative complications, longer hospital stay and higher mortality rate. The open cholecystectomy rate is higher in COVID compared with non -COVID patients. It is recommended to delay the surgical treatment in COVID patients, when it is possible, to decrease morbidity and mortality rates. COVID-19 infection and gangrenous cholecystistis are not absolute contraindications to perform laparoscopic cholecystectomy, in a case by case evaluation, in expert hands.
Collapse
Affiliation(s)
- Belinda De Simone
- Department of Emergency, Digestive and Metabolic Minimally Invasive Surgery, Poissy and Saint Germain en Laye Hospitals, Poissy, France
| | - Fikri M. Abu-Zidan
- grid.43519.3a0000 0001 2193 6666The Research Office, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates., United Arab Emirates University, Al-Ain, UAE
| | - Elie Chouillard
- Department of Emergency, Digestive and Metabolic Minimally Invasive Surgery, Poissy and Saint Germain en Laye Hospitals, Poissy, France
| | - Salomone Di Saverio
- Department of General Surgery, Santa Maria del Soccorso Hospital, San Benedetto del Tronto, Ascoli Piceno, Italy
| | - Massimo Sartelli
- Department of General Surgery, Macerata Hospital, Macerata, Italy
| | - Mauro Podda
- grid.7763.50000 0004 1755 3242Department of Surgical Science, University of Cagliari, Cagliari, Italy
| | - Carlos Augusto Gomes
- Faculdade de Ciência Médicas e da Saúde de Juiz de Fora, Hospital Universitario Terezinha de Jesus (SUPREMA), Juiz de Fora, Brazil
| | - Ernest E. Moore
- grid.239638.50000 0001 0369 638XErnest E. Moore Shock Trauma Center at Denver Health, Denver, CO USA
| | - Susan J. Moug
- grid.8756.c0000 0001 2193 314XDepartment of Surgery, Royal Alexandra Hospital, Paisley and Golden Jubilee National Hospital, University of Glasgow, Glasgow, Scotland
| | - Luca Ansaloni
- grid.18887.3e0000000417581884Department of General Surgery, University Hospital of Pavia, Pavia, Italy
| | - Yoram Kluger
- Department of General Surgery, The Rambam Academic Hospital, Haifa, Israel
| | - Federico Coccolini
- grid.144189.10000 0004 1756 8209Department of General and Emergency Surgery, University Hospital of Pisa, Pisa, Italy
| | | | | | | | - Alessio Giordano
- General Surgery Unit ASL Toscana Centro, Santo Stefano Hospital, Prato, Italy
| | | | | | | | - Amanda Shabana
- grid.8348.70000 0001 2306 7492Emergency Surgery Department, John Radcliffe Hospital, Oxford, UK
| | - Zakaria Andee Dzulkarnaen
- grid.11875.3a0000 0001 2294 3534Department of Surgery, School of Medical Sciences and Hospital USM, Universiti Sains Malaysia, Kubang Kerian, Kelantan Malaysia
| | - Muhammad Asyraf Othman
- grid.11875.3a0000 0001 2294 3534Department of Surgery, School of Medical Sciences and Hospital USM, Universiti Sains Malaysia, Kubang Kerian, Kelantan Malaysia
| | - Mohamad Ikhwan Sani
- grid.11875.3a0000 0001 2294 3534Department of Surgery, School of Medical Sciences and Hospital USM, Universiti Sains Malaysia, Kubang Kerian, Kelantan Malaysia
| | - Andrea Balla
- UOC of General and Minimally Invasive Surgery, Hospital “San Paolo”, Largo Donatori del Sangue 1, 00053 Civitavecchia, Rome, Italy
| | - Rosa Scaramuzzo
- UOC of General and Minimally Invasive Surgery, Hospital “San Paolo”, Largo Donatori del Sangue 1, 00053 Civitavecchia, Rome, Italy
| | - Pasquale Lepiane
- UOC of General and Minimally Invasive Surgery, Hospital “San Paolo”, Largo Donatori del Sangue 1, 00053 Civitavecchia, Rome, Italy
| | - Andrea Bottari
- grid.24704.350000 0004 1759 9494SOD Chirurgia dell’Apparato Digerente, AOU Careggi, Florence, Italy
| | - Fabio Staderini
- grid.24704.350000 0004 1759 9494SOD Chirurgia dell’Apparato Digerente, AOU Careggi, Florence, Italy
| | - Fabio Cianchi
- grid.24704.350000 0004 1759 9494SOD Chirurgia dell’Apparato Digerente, AOU Careggi, Florence, Italy
| | - Andrea Cavallaro
- grid.8158.40000 0004 1757 1969Department of Surgery, University of Catania, Policlinico “G. Rodolico - San Marco” Hospital, Catania, Italy
| | - Antonio Zanghì
- grid.8158.40000 0004 1757 1969Department of Surgery, University of Catania, Policlinico “G. Rodolico - San Marco” Hospital, Catania, Italy
| | - Alessandro Cappellani
- grid.8158.40000 0004 1757 1969Department of Surgery, University of Catania, Policlinico “G. Rodolico - San Marco” Hospital, Catania, Italy
| | | | - Angela Maurizi
- U.O.C. of General Surgery, “Carlo Urbani” Hospital, Jesi, AN Italy
| | | | | | - Asri Che Jusoh
- Department of General Surgery, Hospital Sultan Ismail Petra, 18000 Kuala Krai, Kelantan Malaysia
| | - Karim Abdul Rahman
- Department of General Surgery, Hospital Sultan Ismail Petra, 18000 Kuala Krai, Kelantan Malaysia
| | - Anis Suraya M. Zulkifli
- Department of General Surgery, Hospital Sultan Ismail Petra, 18000 Kuala Krai, Kelantan Malaysia
| | - Barbara Petronio
- Chirurgia Generale e Mininvasiva, San Polo Monfalcone, Monfalcone, GO Italy
| | - Belén Matías-García
- grid.411336.20000 0004 1765 5855Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain
| | - Ana Quiroga-Valcárcel
- grid.411336.20000 0004 1765 5855Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain
| | - Fernando Mendoza-Moreno
- grid.411336.20000 0004 1765 5855Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain
| | - Boyko Atanasov
- grid.35371.330000 0001 0726 0380RIMU, Medical University of Plovdiv, UMHAT Eurohospital, Plovdiv, Bulgaria
| | | | - Ilaria Vecchioni
- Ospedale San Giovanni Decollato Andosilla – ASL, Civita Castellana, Viterbo, VT Italy
| | - Luca Cardinali
- UOC Chirurgia Generale, Ospedale “Madonna del Soccorso”, San Benedetto del Tronto, AP Italy
| | - Grazia Travaglini
- UOC Chirurgia Generale, Ospedale “Madonna del Soccorso”, San Benedetto del Tronto, AP Italy
| | - Elisa Sebastiani
- UOC Chirurgia Generale, Ospedale “Madonna del Soccorso”, San Benedetto del Tronto, AP Italy
| | | | | | - Pasquale Cianci
- grid.416083.80000 0004 1768 5712Lorenzo Bonomo Hospital, ASL BAT, Andria, Puglia Italy
| | - Enrico Restini
- grid.416083.80000 0004 1768 5712Lorenzo Bonomo Hospital, ASL BAT, Andria, Puglia Italy
| | - Sabino Capuzzolo
- grid.416083.80000 0004 1768 5712Lorenzo Bonomo Hospital, ASL BAT, Andria, Puglia Italy
| | - Giuseppe Currò
- grid.411489.10000 0001 2168 2547Generall Surgery Unit, Science of Health Department, “Mater Domini” Hospital, University “Magna Graecia” Medical School, Viale Europa, 88100 Germaneto, Catanzaro Italy
| | - Rosalinda Filippo
- grid.411489.10000 0001 2168 2547Generall Surgery Unit, Science of Health Department, “Mater Domini” Hospital, University “Magna Graecia” Medical School, Viale Europa, 88100 Germaneto, Catanzaro Italy
| | - Michele Rispoli
- grid.411489.10000 0001 2168 2547Generall Surgery Unit, Science of Health Department, “Mater Domini” Hospital, University “Magna Graecia” Medical School, Viale Europa, 88100 Germaneto, Catanzaro Italy
| | - Daniel Aparicio-Sánchez
- grid.411109.c0000 0000 9542 1158Emergency Surgery Unit, Hospital Virgen del Rocío, Seville, Spain
| | | | - Sandra Dios Barbeito
- grid.411109.c0000 0000 9542 1158Emergency Surgery Unit, Hospital Virgen del Rocío, Seville, Spain
| | - Samir Delibegovic
- grid.412410.20000 0001 0682 9061Clinic for Surgery, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina
| | - Amar Kesetovic
- grid.412410.20000 0001 0682 9061Clinic for Surgery, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina
| | - Diego Sasia
- grid.413179.90000 0004 0486 1959Santa Croce and Carle Hospital, Cuneo, Italy
| | - Felice Borghi
- grid.413179.90000 0004 0486 1959Santa Croce and Carle Hospital, Cuneo, Italy
| | - Giorgio Giraudo
- grid.413179.90000 0004 0486 1959Santa Croce and Carle Hospital, Cuneo, Italy
| | - Diego Visconti
- Chirurgia Generale d’Urgenza e PS - AOU Cittá della Salute e della Scienza, Turin, Italy
| | - Emanuele Doria
- Chirurgia Generale d’Urgenza e PS - AOU Cittá della Salute e della Scienza, Turin, Italy
| | - Mauro Santarelli
- Chirurgia Generale d’Urgenza e PS - AOU Cittá della Salute e della Scienza, Turin, Italy
| | - Davide Luppi
- General and Emergency Surgery, ASMN IRCCS REGGIO EMILIA, Reggio Emilia, Italy
| | - Stefano Bonilauri
- General and Emergency Surgery, ASMN IRCCS REGGIO EMILIA, Reggio Emilia, Italy
| | - Ugo Grossi
- grid.5608.b0000 0004 1757 3470Surgery Unit 2, Regional Hospital Treviso, DISCOG, University of Padua, Treviso, Italy
| | - Giacomo Zanus
- grid.5608.b0000 0004 1757 3470Surgery Unit 2, Regional Hospital Treviso, DISCOG, University of Padua, Treviso, Italy
| | - Alberto Sartori
- U.O. Chirurgia Generale e d’Urgenza Ospedale San Valentino, Montebelluna, Treviso, Italy
| | - Giacomo Piatto
- U.O. Chirurgia Generale e d’Urgenza Ospedale San Valentino, Montebelluna, Treviso, Italy
| | - Maurizio De Luca
- U.O. Chirurgia Generale e d’Urgenza Ospedale San Valentino, Montebelluna, Treviso, Italy
| | - Domenico Vita
- grid.5608.b0000 0004 1757 3470Surgery Unit 2, Regional Hospital Treviso, DISCOG, University of Padua, Treviso, Italy
| | - Luigi Conti
- grid.476050.0Department of Surgery, G. Da Saliceto Hospital, AUSL Piacenza, Piacenza, Italy
| | - Patrizio Capelli
- grid.476050.0Department of Surgery, G. Da Saliceto Hospital, AUSL Piacenza, Piacenza, Italy
| | - Gaetano Maria Cattaneo
- grid.476050.0Department of Surgery, G. Da Saliceto Hospital, AUSL Piacenza, Piacenza, Italy
| | - Athanasios Marinis
- grid.414012.20000 0004 0622 6596Styliani-Aikaterini Vederaki, Third Department of Surgery, “Tzaneio” General Hospital, Piraeus, Greece
| | - Styliani-Aikaterini Vederaki
- grid.414012.20000 0004 0622 6596Styliani-Aikaterini Vederaki, Third Department of Surgery, “Tzaneio” General Hospital, Piraeus, Greece
| | - Mehmet Bayrak
- Mehmet Bayrak, Clinic for Surgery, Private Ortadogu Hospital, Adana, Turkey
| | | | | | | | - Yuksel Altinel
- grid.488643.50000 0004 5894 3909Department of General Surgery, Bagcilar Training and Research Hospital, University of Health Science, Istanbul, Turkey
| | - Serhat Meric
- grid.488643.50000 0004 5894 3909Department of General Surgery, Bagcilar Training and Research Hospital, University of Health Science, Istanbul, Turkey
| | - Yunus Emre Aktimur
- grid.488643.50000 0004 5894 3909Department of General Surgery, Bagcilar Training and Research Hospital, University of Health Science, Istanbul, Turkey
| | - Derya Salim Uymaz
- grid.15876.3d0000000106887552General Surgery Department, Faculty of Medicine, Koc University, Istanbul, Turkey
| | - Nail Omarov
- grid.15876.3d0000000106887552General Surgery Department, Faculty of Medicine, Koc University, Istanbul, Turkey
| | - Ibrahim Azamat
- grid.15876.3d0000000106887552General Surgery Department, Faculty of Medicine, Koc University, Istanbul, Turkey
| | - Eftychios Lostoridis
- grid.513828.50000 0004 0623 027X1St Department of Surgery, Kavala General Hospital, Kavala, Greece
| | - Eleni-Aikaterini Nagorni
- grid.513828.50000 0004 0623 027X1St Department of Surgery, Kavala General Hospital, Kavala, Greece
| | - Antonio Pujante
- grid.513828.50000 0004 0623 027X1St Department of Surgery, Kavala General Hospital, Kavala, Greece
| | - Gabriele Anania
- grid.416315.4UO Chirurgia 1, Dipartimento Chirurgico, Arcispedale Sant’Anna, Azienda Ospedaliero-Universitaria’di Ferrara, Ferrara, Italy
| | - Cristina Bombardini
- grid.416315.4UO Chirurgia 1, Dipartimento Chirurgico, Arcispedale Sant’Anna, Azienda Ospedaliero-Universitaria’di Ferrara, Ferrara, Italy
| | - Francesco Bagolini
- grid.416315.4UO Chirurgia 1, Dipartimento Chirurgico, Arcispedale Sant’Anna, Azienda Ospedaliero-Universitaria’di Ferrara, Ferrara, Italy
| | - Emre Gonullu
- grid.459902.30000 0004 0386 5536Sakarya Training and Research Hospital, Sakarya, Turkey
| | - Baris Mantoglu
- grid.459902.30000 0004 0386 5536Sakarya Training and Research Hospital, Sakarya, Turkey
| | - Recayi Capoglu
- grid.459902.30000 0004 0386 5536Sakarya Training and Research Hospital, Sakarya, Turkey
| | - Stefano Cappato
- Department of General Surgery ASL 4, Lavagna Hospital, Genoa, Italy
| | - Elena Muzio
- Department of General Surgery ASL 4, Lavagna Hospital, Genoa, Italy
| | - Elif Colak
- grid.510471.60000 0004 7684 9991Samsun Training and Research Hospital, University of Samsun, Samsun, Turkey
| | - Suleyman Polat
- grid.510471.60000 0004 7684 9991Samsun Training and Research Hospital, University of Samsun, Samsun, Turkey
| | - Zehra Alan Koylu
- grid.510471.60000 0004 7684 9991Samsun Training and Research Hospital, University of Samsun, Samsun, Turkey
| | - Fatih Altintoprak
- grid.49746.380000 0001 0682 3030Department of General Surgery, Faculty of Medicine, Sakarya University, Serdivan, Turkey
| | - Zülfü Bayhan
- grid.49746.380000 0001 0682 3030Department of General Surgery, Faculty of Medicine, Sakarya University, Serdivan, Turkey
| | - Emrah Akin
- grid.49746.380000 0001 0682 3030Department of General Surgery, Faculty of Medicine, Sakarya University, Serdivan, Turkey
| | - Enrico Andolfi
- grid.416351.40000 0004 1789 6237General and Emergency Surgery Unit, San Donato Hospital, Arezzo, Italy
| | - Sulce Rezart
- grid.416351.40000 0004 1789 6237General and Emergency Surgery Unit, San Donato Hospital, Arezzo, Italy
| | - Jae Il Kim
- grid.411633.20000 0004 0371 8173Department of Surgery, Inje University Ilsan Paik Hospital, Goyang, South Korea
| | - Sung Won Jung
- grid.411633.20000 0004 0371 8173Department of Surgery, Inje University Ilsan Paik Hospital, Goyang, South Korea
| | - Yong Chan Shin
- grid.411633.20000 0004 0371 8173Department of Surgery, Inje University Ilsan Paik Hospital, Goyang, South Korea
| | - Octavian Enciu
- grid.8194.40000 0000 9828 7548Elias University Emergency Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| | - Elena Adelina Toma
- grid.8194.40000 0000 9828 7548Elias University Emergency Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| | - Fabio Medas
- grid.7763.50000 0004 1755 3242Department of Surgical Science, University of Cagliari, Cagliari, Italy
| | - Gian Luigi Canu
- grid.7763.50000 0004 1755 3242Department of Surgical Science, University of Cagliari, Cagliari, Italy
| | - Federico Cappellacci
- grid.7763.50000 0004 1755 3242Department of Surgical Science, University of Cagliari, Cagliari, Italy
| | - Fabrizio D’Acapito
- grid.415079.e0000 0004 1759 989XGeneral and Oncologic Surgery, Morgagni-Pierantoni Hospital, AUSL Romagna, Via C. Forlanini 34, 47121 Forlì, Italy
| | - Giorgio Ercolani
- grid.415079.e0000 0004 1759 989XGeneral and Oncologic Surgery, Morgagni-Pierantoni Hospital, AUSL Romagna, Via C. Forlanini 34, 47121 Forlì, Italy
| | - Leonardo Solaini
- grid.415079.e0000 0004 1759 989XGeneral and Oncologic Surgery, Morgagni-Pierantoni Hospital, AUSL Romagna, Via C. Forlanini 34, 47121 Forlì, Italy
| | | | | | - Roberta Gelmini
- grid.7548.e0000000121697570Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia School of Medicine AOU Policlinico Di Modena, Modena, Italy
| | - Francesco Serra
- grid.7548.e0000000121697570Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia School of Medicine AOU Policlinico Di Modena, Modena, Italy
| | - Elena Giulia Rossi
- grid.7548.e0000000121697570Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia School of Medicine AOU Policlinico Di Modena, Modena, Italy
| | - Francesco Fleres
- UOC General Surgery, Hospital Civil of Sondrio, ASST Valtellina e Alto Lario, Sondrio, Italy
| | - Guglielmo Clarizia
- UOC General Surgery, Hospital Civil of Sondrio, ASST Valtellina e Alto Lario, Sondrio, Italy
| | - Alessandro Spolini
- UOC General Surgery, Hospital Civil of Sondrio, ASST Valtellina e Alto Lario, Sondrio, Italy
| | - Francesco Ferrara
- grid.414126.40000 0004 1760 1507Department of Surgery, San Carlo Borromeo Hospital, ASST Santi Paolo e Carlo, Milan, Italy
| | - Gabriela Nita
- grid.458453.b0000 0004 1756 7652AUSL Reggio Emilia, Ospedale Sant’Anna, Castelnuovo ne Monti, Reggio Emilia, Italy
| | - Jlenia Sarnari
- grid.458453.b0000 0004 1756 7652AUSL Reggio Emilia, Ospedale Sant’Anna, Castelnuovo ne Monti, Reggio Emilia, Italy
| | - Mahir Gachabayov
- Department of Abdominal Surgery, Vladimir City Emergency Hospital, Vladimir, Russia
| | - Abakar Abdullaev
- Department of Abdominal Surgery, Vladimir City Emergency Hospital, Vladimir, Russia
| | | | - Gian Marco Palini
- grid.414614.2Chirurgia generale e d’urgenza, Ospedale Infermi di Rimini, AUSL Romagna, Rimini, Italy
| | - Simone Veneroni
- grid.414614.2Chirurgia generale e d’urgenza, Ospedale Infermi di Rimini, AUSL Romagna, Rimini, Italy
| | - Gianluca Garulli
- grid.414614.2Chirurgia generale e d’urgenza, Ospedale Infermi di Rimini, AUSL Romagna, Rimini, Italy
| | - Micaela Piccoli
- Department of General Surgery, Emergencies and New Technologies, Baggiovara Civil Hospital, Modena, Italy
| | - Gianmaria Casoni Pattacini
- Department of General Surgery, Emergencies and New Technologies, Baggiovara Civil Hospital, Modena, Italy
| | - Francesca Pecchini
- Department of General Surgery, Emergencies and New Technologies, Baggiovara Civil Hospital, Modena, Italy
| | - Giulio Argenio
- UOC Chirurgia d’Urgenza, AOU San Giovanni di Dio e Ruggi d’Aragona, Salerno, Italy
| | | | - Giuseppe Brisinda
- grid.414603.4Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy
| | - Silvia Tedesco
- grid.414603.4Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy
| | - Pietro Fransvea
- grid.414603.4Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy
| | - Giuseppe Ietto
- grid.18147.3b0000000121724807General, Emergency and Transplant Surgery Department, ASST-Settelaghi and University of Insubria, Varese, Italy
| | - Caterina Franchi
- grid.18147.3b0000000121724807General, Emergency and Transplant Surgery Department, ASST-Settelaghi and University of Insubria, Varese, Italy
| | - Giulio Carcano
- grid.18147.3b0000000121724807General, Emergency and Transplant Surgery Department, ASST-Settelaghi and University of Insubria, Varese, Italy
| | - Gennaro Martines
- General Surgery Unit, Azienda Ospedaliero Universitaria Policlinico Bari - Italy, Bari, Italy
| | - Giuseppe Trigiante
- General Surgery Unit, Azienda Ospedaliero Universitaria Policlinico Bari - Italy, Bari, Italy
| | - Giulia Negro
- General Surgery Unit, Azienda Ospedaliero Universitaria Policlinico Bari - Italy, Bari, Italy
| | - Gustavo Machain Vega
- grid.412213.70000 0001 2289 5077Department of Surgery, Hospital de Clinicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay
| | - Agustín Rodríguez González
- grid.412213.70000 0001 2289 5077Department of Surgery, Hospital de Clinicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay
| | - Leonardo Ojeda
- grid.412213.70000 0001 2289 5077Department of Surgery, Hospital de Clinicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay
| | - Gaetano Piccolo
- grid.4708.b0000 0004 1757 2822Unit of HepatoBilioPancreatic and Digestive Surgery, Department of Health Sciences, San Paolo Hospital, University of Milan, Via Di Rudinì 8, 20142 Milan, Italy
| | - Andrea Bondurri
- grid.4708.b0000 0004 1757 2822Department of General Surgery, Department of Biomedical and Clinical Sciences Luigi Sacco, Luigi Sacco University Hospital, Università degli Studi di Milano, Milan, Italy
| | - Anna Maffioli
- grid.4708.b0000 0004 1757 2822Department of General Surgery, Department of Biomedical and Clinical Sciences Luigi Sacco, Luigi Sacco University Hospital, Università degli Studi di Milano, Milan, Italy
| | - Claudio Guerci
- grid.4708.b0000 0004 1757 2822Department of General Surgery, Department of Biomedical and Clinical Sciences Luigi Sacco, Luigi Sacco University Hospital, Università degli Studi di Milano, Milan, Italy
| | - Boo Han Sin
- HPB Unit, Department of Surgery, Hospital Canselor Tuanku Muhriz, Kuala Lumpur, Malaysia
| | - Zamri Zuhdi
- HPB Unit, Department of Surgery, Hospital Canselor Tuanku Muhriz, Kuala Lumpur, Malaysia
| | - Azlanudin Azman
- HPB Unit, Department of Surgery, Hospital Canselor Tuanku Muhriz, Kuala Lumpur, Malaysia
| | - Hussam Mousa
- grid.43519.3a0000 0001 2193 6666College of Medicine, Tawam Hospital, UAE University, Al-Ain, UAE
| | - Shadi al Bahri
- grid.43519.3a0000 0001 2193 6666College of Medicine, Tawam Hospital, UAE University, Al-Ain, UAE
| | - Goran Augustin
- grid.412688.10000 0004 0397 9648Department of Surgery, University Hospital Centre, Zagreb, Croatia
| | - Ivan Romic
- grid.412688.10000 0004 0397 9648Department of Surgery, University Hospital Centre, Zagreb, Croatia
| | - Trpimir Moric
- grid.412688.10000 0004 0397 9648Department of Surgery, University Hospital Centre, Zagreb, Croatia
| | | | - Jacopo Andreuccetti
- grid.412725.72nd Department of General Surgery, ASST Spedali Civili of Brescia, Brescia, Italy
| | - Giusto Pignata
- grid.412725.72nd Department of General Surgery, ASST Spedali Civili of Brescia, Brescia, Italy
| | - Rossella D’Alessio
- grid.412725.72nd Department of General Surgery, ASST Spedali Civili of Brescia, Brescia, Italy
| | - Jakub Kenig
- grid.5522.00000 0001 2162 9631Department of General, Gastrointestinal, Oncologic Surgery and Transplantology, Jagiellonian University Medical College, Kraków, Poland
| | - Urszula Skorus
- grid.5522.00000 0001 2162 9631Department of General, Gastrointestinal, Oncologic Surgery and Transplantology, Jagiellonian University Medical College, Kraków, Poland
| | - Gustavo Pereira Fraga
- grid.411087.b0000 0001 0723 2494Division of Trauma Surgery, School of Medical Sciences, University of Campinas (Unicamp), Campinas, Brazil
| | - Elcio Shiyoiti Hirano
- grid.411087.b0000 0001 0723 2494Division of Trauma Surgery, School of Medical Sciences, University of Campinas (Unicamp), Campinas, Brazil
| | | | - Arda Isik
- grid.412176.70000 0001 1498 7262School of Medicine, Erzincan University, Erzincan, Turkey
| | - Eray Kurnaz
- grid.412176.70000 0001 1498 7262School of Medicine, Erzincan University, Erzincan, Turkey
| | | | - Ameer Afzal
- grid.412129.d0000 0004 0608 7688King Edward Medical University, Lahore, Pakistan
| | - Ali Akbar
- grid.412129.d0000 0004 0608 7688King Edward Medical University, Lahore, Pakistan
| | | | - Konstantinos Lasithiotakis
- grid.412481.a0000 0004 0576 5678Department of General Surgery, University General Hospital of Heraklion, 71110 Heraklion, Crete, Greece
| | - Emmanuel Chrysos
- grid.412481.a0000 0004 0576 5678Department of General Surgery, University General Hospital of Heraklion, 71110 Heraklion, Crete, Greece
| | - Koray Das
- Department of General Surgery, Adana City Training and Research Hospital, University of Health Sciences, Adana, Turkey
| | - Nazmi Özer
- Department of General Surgery, Adana City Training and Research Hospital, University of Health Sciences, Adana, Turkey
| | - Ahmet Seker
- Department of General Surgery, Adana City Training and Research Hospital, University of Health Sciences, Adana, Turkey
| | | | | | | | - Konstantinos Bouliaris
- Surgical Department, Koutlimbaneio and Triantafylleio General Hospital of Larissa, Larisa, Greece
| | - George Koukoulis
- Surgical Department, Koutlimbaneio and Triantafylleio General Hospital of Larissa, Larisa, Greece
| | | | - Andrea Lucchi
- U.O. Chirurgia Generale Ospedale “Ceccarini” Riccione, Riccione, Italy
| | - Laura Agostinelli
- U.O. Chirurgia Generale Ospedale “Ceccarini” Riccione, Riccione, Italy
| | - Antonio Taddei
- grid.24704.350000 0004 1759 9494Hepatobiliary Surgery, Department of Clinical and Experimental Medicine, University of Florence, AOU Careggi, Florence, Italy
| | - Laura Fortuna
- grid.24704.350000 0004 1759 9494Hepatobiliary Surgery, Department of Clinical and Experimental Medicine, University of Florence, AOU Careggi, Florence, Italy
| | - Carlotta Agostini
- grid.24704.350000 0004 1759 9494Hepatobiliary Surgery, Department of Clinical and Experimental Medicine, University of Florence, AOU Careggi, Florence, Italy
| | - Leo Licari
- grid.10776.370000 0004 1762 5517Department of Surgical, Oncological and Oral Sciences (DICHIRONS), Policlinico P. Giaccone, University of Palermo, Via Liborio Giuffré 5, 90127 Palermo, Italy
| | - Simona Viola
- grid.10776.370000 0004 1762 5517University of Palermo, Palermo, Italy
| | - Cosimo Callari
- Department of Surgery, Buccheri La Ferla Hospital, Via Messina Marine, 197, 90123 Palermo, Italy
| | - Letizia Laface
- Department of General Surgery, Vittorio Emanuele III Hospital, Carate Brianza - ASST Brianza, Carate Brianza, Italy
| | - Emmanuele Abate
- Department of General Surgery, Vittorio Emanuele III Hospital, Carate Brianza - ASST Brianza, Carate Brianza, Italy
| | - Massimiliano Casati
- Department of General Surgery, Vittorio Emanuele III Hospital, Carate Brianza - ASST Brianza, Carate Brianza, Italy
| | | | | | - Linda Gabellini
- Chirurgia Generale, Ospedale San Giovanni Di Dio, Florence, Italy
| | - Lorenzo Tosi
- grid.6292.f0000 0004 1757 1758Residency Program in General Surgery, University of Bologna, Bologna, Italy
| | - Anna Guariniello
- grid.415207.50000 0004 1760 3756Section of Emergency Surgery, Department of Surgery, S.Maria delle Croci Hospital Ravenna, Ravenna, Italy
| | - Federico Zanzi
- grid.415207.50000 0004 1760 3756Section of Emergency Surgery, Department of Surgery, S.Maria delle Croci Hospital Ravenna, Ravenna, Italy
| | - Lovenish Bains
- grid.414698.60000 0004 1767 743XDepartment of Surgery, Maulana Azad Medical College and Nayak Hospital, New Delhi, 110002 India
| | - Larysa Sydorchuk
- grid.445372.30000 0004 4906 2392Bukovinian State Medical University, Chernivtsi, Ukraine
| | - Oksana Iftoda
- grid.445372.30000 0004 4906 2392Bukovinian State Medical University, Chernivtsi, Ukraine
| | - Andrii Sydorchuk
- grid.445372.30000 0004 4906 2392Bukovinian State Medical University, Chernivtsi, Ukraine
| | | | | | | | - Michela Monteleone
- Andrea Costanzi, Carlo Riva, O.U. of General Surgery, San Leopoldo Mandic Hospital, Merate, ASST, Lecco, Italy
| | - Andrea Costanzi
- Andrea Costanzi, Carlo Riva, O.U. of General Surgery, San Leopoldo Mandic Hospital, Merate, ASST, Lecco, Italy
| | - Carlo Riva
- Andrea Costanzi, Carlo Riva, O.U. of General Surgery, San Leopoldo Mandic Hospital, Merate, ASST, Lecco, Italy
| | - Maciej Walędziak
- grid.415641.30000 0004 0620 0839Department of General, Oncological, Metabolic and Thoracic Surgery, Military Institute of Medicine, Warsaw, Poland
| | - Andrzej Kwiatkowski
- grid.415641.30000 0004 0620 0839Department of General, Oncological, Metabolic and Thoracic Surgery, Military Institute of Medicine, Warsaw, Poland
| | - Łukasz Czyżykowski
- grid.415641.30000 0004 0620 0839Department of General, Oncological, Metabolic and Thoracic Surgery, Military Institute of Medicine, Warsaw, Poland
| | - Piotr Major
- grid.5522.00000 0001 2162 9631Department of General and Emergency Surgery, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland
| | - Marcin Strzałka
- grid.5522.00000 0001 2162 9631Department of General and Emergency Surgery, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland
| | - Maciej Matyja
- grid.5522.00000 0001 2162 9631Department of General and Emergency Surgery, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland
| | - Michal Natkaniec
- grid.5522.00000 0001 2162 9631Department of General and Emergency Surgery, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland
| | - Maria Rosaria Valenti
- U.O. General Surgery, Azienda Ospedaliera Universitaria “Policlinico - San Marco”, Catania, Italy
| | | | - Maria Sotiropoulou
- grid.414655.70000 0004 4670 43293Rd Surgical Department, Evangelismos General Hospital, Athens, Greece
| | - Stylianos Kapiris
- grid.414655.70000 0004 4670 43293Rd Surgical Department, Evangelismos General Hospital, Athens, Greece
| | - Damien Massalou
- grid.410528.a0000 0001 2322 4179Department of Emergency Surgery, Centre Hospitalier Universitaire de Nice (CHU de Nice), Université Côte d’Azur, Nice, France
| | | | | | - Rossella Gioco
- General Surgery, Azienda Policlinico San Marco, Catania, Italy
| | - Matteo Uccelli
- General and Oncological Surgery Department, San Marco Hospital GSD, Zingonia, BG Italy
| | - Marta Bonaldi
- General and Oncological Surgery Department, San Marco Hospital GSD, Zingonia, BG Italy
| | - Stefano Olmi
- General and Oncological Surgery Department, San Marco Hospital GSD, Zingonia, BG Italy
| | - Matteo Nardi
- San Giovanni Calibita Hospital- Fondazione Fatebenefratelli, Rome, Italy
| | - Giada Livadoti
- San Giovanni Calibita Hospital- Fondazione Fatebenefratelli, Rome, Italy
| | - Cristian Mesina
- grid.452359.c0000 0004 4690 999XDepartment of Surgery, Emergency County Hospital of Craiova, Craiova, Romania
| | - Theodor Viorel Dumitrescu
- grid.452359.c0000 0004 4690 999XDepartment of Surgery, Emergency County Hospital of Craiova, Craiova, Romania
| | - Mihai Calin Ciorbagiu
- grid.452359.c0000 0004 4690 999XDepartment of Surgery, Emergency County Hospital of Craiova, Craiova, Romania
| | - Michele Ammendola
- grid.411489.10000 0001 2168 2547Science of Health Department, Digestive Surgery Unit, “Mater Domini” Hospital, University “Magna Graecia” Medical School, Viale Europa, 88100 Germaneto, Catanzaro Italy
| | - Giorgio Ammerata
- grid.411489.10000 0001 2168 2547Science of Health Department, Digestive Surgery Unit, “Mater Domini” Hospital, University “Magna Graecia” Medical School, Viale Europa, 88100 Germaneto, Catanzaro Italy
| | - Roberto Romano
- grid.411489.10000 0001 2168 2547Science of Health Department, Digestive Surgery Unit, “Mater Domini” Hospital, University “Magna Graecia” Medical School, Viale Europa, 88100 Germaneto, Catanzaro Italy
| | - Mihail Slavchev
- Department of General Surgery, University Hospital Eurohospital, Plovdiv, Bulgaria
| | - Evangelos P. Misiakos
- grid.5216.00000 0001 2155 08003Rd Department of Surgery, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - Emmanouil Pikoulis
- grid.5216.00000 0001 2155 08003Rd Department of Surgery, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - Dimitrios Papaconstantinou
- grid.5216.00000 0001 2155 08003Rd Department of Surgery, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - Mohamed Elbahnasawy
- grid.412258.80000 0000 9477 7793Emergency Medicine and Traumatology Department, Tanta University Faculty of Medicine, Tanta, Egypt
| | - Sherief Abdel-elsalam
- grid.412258.80000 0000 9477 7793Tropical Medicine and Infectious Diseases, Faculty of Medicine, Tanta University, Tanta, Egypt
| | - Daniel M. Felsenreich
- grid.22937.3d0000 0000 9259 8492Division of Visceral Surgery, Department of General Surgery, Medical University of Vienna, Vienna, Austria
| | - Julia Jedamzik
- grid.22937.3d0000 0000 9259 8492Division of Visceral Surgery, Department of General Surgery, Medical University of Vienna, Vienna, Austria
| | - Nikolaos V. Michalopoulos
- grid.5216.00000 0001 2155 08004Rd Department of Surgery Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - Theodoros A. Sidiropoulos
- grid.5216.00000 0001 2155 08004Rd Department of Surgery Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - Maria Papadoliopoulou
- grid.5216.00000 0001 2155 08004Rd Department of Surgery Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - Nicola Cillara
- grid.459832.1Surgery Department, Santissima Trinità Hospital, Cagliari, Italy
| | - Antonello Deserra
- grid.459832.1Surgery Department, Santissima Trinità Hospital, Cagliari, Italy
| | | | - Ionuţ Negoi
- grid.8194.40000 0000 9828 7548General Surgery Department, Carol Davila University of Medicine and Pharmacy, Emergency Hospital of Bucharest, Bucharest, Romania
| | - Dimitrios Schizas
- grid.411565.20000 0004 0621 2848First Department of Surgery, National and Kapodistrian University of Athens, Laiko General Hospital, 11527 Athens, Greece
| | - Athanasios Syllaios
- grid.411565.20000 0004 0621 2848First Department of Surgery, National and Kapodistrian University of Athens, Laiko General Hospital, 11527 Athens, Greece
| | - Ilias Vagios
- grid.411565.20000 0004 0621 2848First Department of Surgery, National and Kapodistrian University of Athens, Laiko General Hospital, 11527 Athens, Greece
| | - Stavros Gourgiotis
- grid.5335.00000000121885934Addenbrooke’s Hospital, Cambridge University, Cambridge, UK
| | - Nick Dai
- grid.5335.00000000121885934Addenbrooke’s Hospital, Cambridge University, Cambridge, UK
| | - Rekha Gurung
- grid.5335.00000000121885934Addenbrooke’s Hospital, Cambridge University, Cambridge, UK
| | - Marcus Norrey
- grid.5335.00000000121885934Addenbrooke’s Hospital, Cambridge University, Cambridge, UK
| | - Antonio Pesce
- grid.8484.00000 0004 1757 2064Department of Surgery, Delta Hospital, Azienda USL of Ferrara, University of Ferrara, Ferrara, Italy
| | - Carlo Vittorio Feo
- grid.8484.00000 0004 1757 2064Department of Surgery, Delta Hospital, Azienda USL of Ferrara, University of Ferrara, Ferrara, Italy
| | - Nicolo’ Fabbri
- grid.8484.00000 0004 1757 2064Department of Surgery, Delta Hospital, Azienda USL of Ferrara, University of Ferrara, Ferrara, Italy
| | - Nikolaos Machairas
- grid.5216.00000 0001 2155 08002Nd Department of Propaedeutic Surgery, National and Kapodistrian University of Athens, General Hospital Laiko, Athens, Greece
| | - Panagiotis Dorovinis
- grid.5216.00000 0001 2155 08002Nd Department of Propaedeutic Surgery, National and Kapodistrian University of Athens, General Hospital Laiko, Athens, Greece
| | - Myrto D. Keramida
- grid.5216.00000 0001 2155 08002Nd Department of Propaedeutic Surgery, National and Kapodistrian University of Athens, General Hospital Laiko, Athens, Greece
| | - Francesk Mulita
- grid.412458.eDepartment of Surgery, General University Hospital of Patras, Patras, Greece
| | | | - Michail Vailas
- grid.412458.eDepartment of Surgery, General University Hospital of Patras, Patras, Greece
| | - Omer Yalkin
- Department of Surgical Oncology and Gastroenterological Surgery, Bursa City Hospital, Bursa, Turkey
| | - Nidal Iflazoglu
- Department of Surgical Oncology and Gastroenterological Surgery, Bursa City Hospital, Bursa, Turkey
| | - Direnc Yigit
- Department of Surgical Oncology and Gastroenterological Surgery, Bursa City Hospital, Bursa, Turkey
| | - Oussama Baraket
- grid.265234.40000 0001 2177 9066Department of General Surgery, Habib Bougatfa Hospital, University Tunis El Manar, Bizerte, Tunisia
| | - Karim Ayed
- grid.265234.40000 0001 2177 9066Department of General Surgery, Habib Bougatfa Hospital, University Tunis El Manar, Bizerte, Tunisia
| | - Mohamed hedi Ghalloussi
- grid.265234.40000 0001 2177 9066Department of General Surgery, Habib Bougatfa Hospital, University Tunis El Manar, Bizerte, Tunisia
| | - Parmenion Patias
- grid.414012.20000 0004 0622 65962nd Department of Surgery, General Hospital of Athens “G.Gennimatas”, Athens, Greece
| | - Georgios Ntokos
- grid.414012.20000 0004 0622 65962nd Department of Surgery, General Hospital of Athens “G.Gennimatas”, Athens, Greece
| | - Razrim Rahim
- grid.462995.50000 0001 2218 9236Department of Surgery, Universiti Sains Islam Malaysia, Nilai, Malaysia
| | - Miklosh Bala
- grid.9619.70000 0004 1937 0538Department of General Surgery and Trauma, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
| | - Asaf Kedar
- grid.9619.70000 0004 1937 0538Department of General Surgery and Trauma, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
| | - Robert G. Sawyer
- grid.268187.20000 0001 0672 1122Western Michigan University School of Medicine, Kalamazoo, USA
| | - Anna Trinh
- grid.268187.20000 0001 0672 1122Western Michigan University School of Medicine, Kalamazoo, USA
| | - Kelsey Miller
- grid.268187.20000 0001 0672 1122Western Michigan University School of Medicine, Kalamazoo, USA
| | | | - Ruslan Knut
- Regional Emergency Hospital, Chernivtsi, Ukraine
| | | | | | - Zeynep Ozkan
- General Surgery Clinic, Elazig Fethi Sekin City Hospital, Elazig, Turkey
| | - Saleh Abdel Kader
- Egypt and NMC Specialty Hospital Al Ain, Ain Shams University, Al-Ain, UAE
| | - Sanjay Gupta
- grid.413220.60000 0004 1767 2831Government Medical College and Hospital, Chandigarh, India
| | - Monika Gureh
- grid.413220.60000 0004 1767 2831Government Medical College and Hospital, Chandigarh, India
| | - Sara Saeidi
- grid.411583.a0000 0001 2198 6209Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Mohsen Aliakbarian
- grid.411583.a0000 0001 2198 6209Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Amin Dalili
- grid.411583.a0000 0001 2198 6209Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Tomohisa Shoko
- grid.410818.40000 0001 0720 6587Department of Emergency and Critical Care Medicine, Department of Acute Care Surgery Center, Adachi Medical Center, Tokyo Women’s Medical University, Tokyo, Japan
| | - Mitsuaki Kojima
- grid.410818.40000 0001 0720 6587Department of Emergency and Critical Care Medicine, Department of Acute Care Surgery Center, Adachi Medical Center, Tokyo Women’s Medical University, Tokyo, Japan
| | - Raira Nakamoto
- grid.410818.40000 0001 0720 6587Department of Emergency and Critical Care Medicine, Department of Acute Care Surgery Center, Adachi Medical Center, Tokyo Women’s Medical University, Tokyo, Japan
| | - Semra Demirli Atici
- grid.414882.30000 0004 0643 0132Department of General Surgery, University of Health Sciences Tepecik Training and Research Hospital, Izmir, Turkey
| | - Gizem Kilinc Tuncer
- grid.414882.30000 0004 0643 0132Department of General Surgery, University of Health Sciences Tepecik Training and Research Hospital, Izmir, Turkey
| | - Tayfun Kaya
- grid.414882.30000 0004 0643 0132Department of General Surgery, University of Health Sciences Tepecik Training and Research Hospital, Izmir, Turkey
| | | | - Stefano Rossi
- grid.416357.2Department of General and Emergency Surgery, San Filippo Neri Hospital, ASL Roma 1, Rome, Italy
| | - Biagio Picardi
- grid.416357.2Department of General and Emergency Surgery, San Filippo Neri Hospital, ASL Roma 1, Rome, Italy
| | - Simone Rossi del Monte
- grid.416357.2Department of General and Emergency Surgery, San Filippo Neri Hospital, ASL Roma 1, Rome, Italy
| | - Tania Triantafyllou
- grid.5216.00000 0001 2155 0800Department of Surgery, Hippocration General Hospital of Athens, University of Athens, Athens, Greece
| | - Dimitrios Theodorou
- grid.5216.00000 0001 2155 0800Department of Surgery, Hippocration General Hospital of Athens, University of Athens, Athens, Greece
| | - Tadeja Pintar
- grid.29524.380000 0004 0571 7705Department of Abdominal Surgery, University Medical Center Ljubljana, Ljubljana, Slovenia
| | - Jure Salobir
- grid.29524.380000 0004 0571 7705Department of Abdominal Surgery, University Medical Center Ljubljana, Ljubljana, Slovenia
| | - Dimitrios K. Manatakis
- grid.414025.60000 0004 0638 8093Vasileios Acheimastos, Athens Naval and Veterans Hospital, Athens, Greece
| | - Nikolaos Tasis
- grid.414025.60000 0004 0638 8093Vasileios Acheimastos, Athens Naval and Veterans Hospital, Athens, Greece
| | - Vasileios Acheimastos
- grid.414025.60000 0004 0638 8093Vasileios Acheimastos, Athens Naval and Veterans Hospital, Athens, Greece
| | - Orestis Ioannidis
- grid.414012.20000 0004 0622 65964Th Department of Surgery, Medical School Aristotle University of Thessaloniki, General Hospital “George Papanikolaou”, Thessaloniki, Greece
| | - Lydia Loutzidou
- grid.414012.20000 0004 0622 65964Th Department of Surgery, Medical School Aristotle University of Thessaloniki, General Hospital “George Papanikolaou”, Thessaloniki, Greece
| | - Savvas Symeonidis
- grid.414012.20000 0004 0622 65964Th Department of Surgery, Medical School Aristotle University of Thessaloniki, General Hospital “George Papanikolaou”, Thessaloniki, Greece
| | - Tiago Correia de Sá
- grid.466592.aGeneral Surgery Department, Centro Hospitalar Do Tâmega e Sousa Penafiel, Penafiel, Portugal
| | - Mónica Rocha
- grid.466592.aGeneral Surgery Department, Centro Hospitalar Do Tâmega e Sousa Penafiel, Penafiel, Portugal
| | - Tommaso Guagni
- grid.24704.350000 0004 1759 9494Department of general surgery, Careggi University Hospital, Florence, Italy
| | - Desiré Pantalone
- grid.24704.350000 0004 1759 9494Department of general surgery, Careggi University Hospital, Florence, Italy
| | - Gherardo Maltinti
- grid.24704.350000 0004 1759 9494Department of general surgery, Careggi University Hospital, Florence, Italy
| | | | - Wafaa Abdel-elsalam
- grid.411978.20000 0004 0578 3577Anesthesia and Surgical Intensive Care Department, Faculty of Medicine, Kafrelsheikh University, Kafrelsheikh, Egypt
| | - Basma Ghoneim
- grid.411978.20000 0004 0578 3577Anesthesia and Surgical Intensive Care Department, Faculty of Medicine, Kafrelsheikh University, Kafrelsheikh, Egypt
| | - José Antonio López-Ruiz
- grid.411375.50000 0004 1768 164XAngeles Gil-Olarte, Estela Romero-Vargas, Hospital Universitario Virgen Macarena, Seville, Spain
| | - Yasin Kara
- grid.414850.c0000 0004 0642 8921General Surgery Clinic Health Sciences University Kanuni Sultan Süleyman Training and Research Hospital, Istanbul, Turkey
| | - Syaza Zainudin
- grid.265727.30000 0001 0417 0814Faculty of Medicine and Health Sciences, Queen Elisabeth Hospital, Universiti Malaysia Sabah, Kota Kinabalu, Malaysia
| | - Firdaus Hayati
- grid.265727.30000 0001 0417 0814Faculty of Medicine and Health Sciences, Queen Elisabeth Hospital, Universiti Malaysia Sabah, Kota Kinabalu, Malaysia
| | - Nornazirah Azizan
- grid.265727.30000 0001 0417 0814Faculty of Medicine and Health Sciences, Queen Elisabeth Hospital, Universiti Malaysia Sabah, Kota Kinabalu, Malaysia
| | - Victoria Tan Phooi Khei
- grid.265727.30000 0001 0417 0814Department of Surgery, Queen Elizabeth Hospital, Universiti Malaysia Sabah, Kota Kinabalu, Malaysia
| | - Rebecca Choy Xin Yi
- grid.265727.30000 0001 0417 0814Department of Surgery, Queen Elizabeth Hospital, Universiti Malaysia Sabah, Kota Kinabalu, Malaysia
| | - Harivinthan Sellappan
- grid.265727.30000 0001 0417 0814Department of Surgery, Queen Elizabeth Hospital, Universiti Malaysia Sabah, Kota Kinabalu, Malaysia
| | | | | | - Ana Tvaladze
- N.Kipshidze Central University Hospital, Tbilisi, Georgia
| | - Caterina Froiio
- grid.4708.b0000 0004 1757 2822IRCCS Policlinico San Donato, University of Milan, Milan, Italy
| | - Daniele Bernardi
- grid.4708.b0000 0004 1757 2822IRCCS Policlinico San Donato, University of Milan, Milan, Italy
| | - Luigi Bonavina
- grid.4708.b0000 0004 1757 2822IRCCS Policlinico San Donato, University of Milan, Milan, Italy
| | - Angeles Gil-Olarte
- grid.411375.50000 0004 1768 164XAngeles Gil-Olarte, Estela Romero-Vargas, Hospital Universitario Virgen Macarena, Seville, Spain
| | - Sebastiano Grassia
- General Surgery Unit, S. Leonardo Hospital, Castellammare Di Stabia, Naples, Italy
| | - Estela Romero-Vargas
- grid.411375.50000 0004 1768 164XAngeles Gil-Olarte, Estela Romero-Vargas, Hospital Universitario Virgen Macarena, Seville, Spain
| | - Francesco Bianco
- General Surgery Unit, S. Leonardo Hospital, Castellammare Di Stabia, Naples, Italy
| | - Andrew A. Gumbs
- Department of Emergency, Digestive and Metabolic Minimally Invasive Surgery, Poissy and Saint Germain en Laye Hospitals, Poissy, France
| | - Agron Dogjani
- Department of General Surgery, University Hospital of Tirana, Tirana, Albania
| | - Ferdinando Agresta
- Department of General Surgery, AULSS2 Trevigiana del Veneto, Ospedale di Vittorio Veneto, Vittorio Veneto, TV Italy
| | - Andrey Litvin
- grid.410686.d0000 0001 1018 9204Department of Surgical Disciplines, Immanuel Kant Baltic Federal University, Regional Clinical Hospital, Kalingrad, Russia
| | - Zsolt J. Balogh
- grid.414724.00000 0004 0577 6676Department of Traumatology, John Hunter Hospital and University of Newcastle, Newcastle, NSW Australia
| | - George Gendrikson
- grid.410686.d0000 0001 1018 9204Department of Surgical Disciplines, Immanuel Kant Baltic Federal University, Regional Clinical Hospital, Kalingrad, Russia
| | - Costanza Martino
- Anesthesia and Intensive Care Unit, Umberto I Hospital, AUSL Romagna, Lugo, Italy
| | - Dimitrios Damaskos
- grid.4305.20000 0004 1936 7988Department of General and Emergency Surgery, Royal Infirmary of Edinburgh, University of Edinburgh, Edinburgh, UK
| | - Nikolaos Pararas
- grid.411335.10000 0004 1758 7207Department of General Surgery, Dr. Sulaiman Al Habib Hospital, Alfaisal University, Riyadh, Saudi Arabia
| | - Andrew Kirkpatrick
- grid.414959.40000 0004 0469 2139General, Acute Care, Abdominal Wall Reconstruction, and Trauma Surgery, Foothills Medical Centre, Calgary, AB Canada
| | - Mikhail Kurtenkov
- grid.410686.d0000 0001 1018 9204Department of Surgical Disciplines, Immanuel Kant Baltic Federal University, Regional Clinical Hospital, Kalingrad, Russia
| | - Felipe Couto Gomes
- Faculdade de Ciência Médicas e da Saúde de Juiz de Fora, Hospital Universitario Terezinha de Jesus (SUPREMA), Juiz de Fora, Brazil
| | - Adolfo Pisanu
- grid.7763.50000 0004 1755 3242Department of Surgical Science, University of Cagliari, Cagliari, Italy
| | - Oreste Nardello
- grid.7763.50000 0004 1755 3242Department of Surgical Science, University of Cagliari, Cagliari, Italy
| | | | - Hager Aref
- Department of Emergency, Digestive and Metabolic Minimally Invasive Surgery, Poissy and Saint Germain en Laye Hospitals, Poissy, France
| | - Nicola de’ Angelis
- grid.412116.10000 0004 1799 3934Unit of Digestive and HPB Surgery, CARE Department, Henri Mondor Hospital and University Paris-Est, Creteil, France
| | - Vanni Agnoletti
- grid.414682.d0000 0004 1758 8744Department of General and Trauma Surgery, Bufalini Hospital, Cesena, Italy
| | - Antonio Biondi
- grid.8158.40000 0004 1757 1969Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy
| | - Marco Vacante
- grid.8158.40000 0004 1757 1969Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy
| | - Giulia Griggio
- grid.8158.40000 0004 1757 1969Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy
| | - Roberta Tutino
- grid.10776.370000 0004 1762 5517Chirurgia 1; Dipartimento di Discipline Chirurgiche , Oncologiche e Stomatologiche (DI.CHIR.ON.S), Ospedale “Ca’Foncell”; Univerità degli studi di Palermo, Treviso; Palermo, Italy
| | - Marco Massani
- grid.10776.370000 0004 1762 5517Chirurgia 1; Dipartimento di Discipline Chirurgiche , Oncologiche e Stomatologiche (DI.CHIR.ON.S), Ospedale “Ca’Foncell”; Univerità degli studi di Palermo, Treviso; Palermo, Italy
| | - Giovanni Bisetto
- grid.5608.b0000 0004 1757 3470Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologica (DI.SC.O.G.), Chirurgia 1-Ospedale “Ca Foncello”- Treviso, Università degli Studi di Padova, Padua, Italy
| | - Savino Occhionorelli
- grid.8484.00000 0004 1757 2064Department of General Surgery, Arcispedale Sant’Anna-University of Ferrara, Ferrara, Italy
| | - Dario Andreotti
- grid.8484.00000 0004 1757 2064Department of General Surgery, Arcispedale Sant’Anna-University of Ferrara, Ferrara, Italy
| | - Domenico Lacavalla
- grid.8484.00000 0004 1757 2064Department of General Surgery, Arcispedale Sant’Anna-University of Ferrara, Ferrara, Italy
| | - Walter L. Biffl
- grid.415401.5Department of Emergency and Trauma Surgery, Scripps Clinic Medical Group, La Jolla, CA USA
| | - Fausto Catena
- grid.414682.d0000 0004 1758 8744Department of General and Trauma Surgery, Bufalini Hospital, Cesena, Italy
| |
Collapse
|
132
|
Karlafti E, Paramythiotis D, Pantazi K, Georgakopoulou VE, Kaiafa G, Papalexis P, Protopapas AA, Ztriva E, Fyntanidou V, Savopoulos C. Drug-Induced Liver Injury in Hospitalized Patients during SARS-CoV-2 Infection. Medicina (B Aires) 2022; 58:medicina58121848. [PMID: 36557050 PMCID: PMC9782075 DOI: 10.3390/medicina58121848] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Revised: 12/08/2022] [Accepted: 12/13/2022] [Indexed: 12/23/2022] Open
Abstract
In the last few years, the world has had to face the SARS-CoV-2 infection and its multiple effects. Even though COVID-19 was first considered to be a respiratory disease, it has an extended clinical spectrum with symptoms occurring in many tissues, and it is now identified as a systematic disease. Therefore, various drugs are used during the therapy of hospitalized COVID-19 patients. Studies have shown that many of these drugs could have adverse side-effects, including drug-induced liver injury-also known as DILI-which is the focus of our review. Despite the consistent findings, the pathophysiological mechanism behind DILI in COVID-19 disease is still complex, and there are a few risk factors related to it. However, when it comes to the diagnosis, there are specific algorithms (including the RUCAM algorithm) and biomarkers that can assist in identifying DILI and which we will analyze in our review. As indicated by the title, a variety of drugs are associated with this COVID-19-related complication, including systemic corticosteroids, drugs used for the therapy of uncontrolled cytokine storm, as well as antiviral, anti-inflammatory, and anticoagulant drugs. Bearing in mind that hepatotoxicity is very likely to occur during COVID-19, especially in patients treated with multiple medications, we will also refer to the use of other drugs used for DILI therapy in an effort to control and prevent a severe and long-term outcome.
Collapse
Affiliation(s)
- Eleni Karlafti
- Emergency Department, AHEPA University General Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece
- First Propaedeutic Department of Internal Medicine, AHEPA University General Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece
- Correspondence: ; Tel.: +231-330-3110
| | - Daniel Paramythiotis
- First Propaedeutic Department of Surgery, AHEPA University General Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece
| | - Konstantina Pantazi
- First Propaedeutic Department of Internal Medicine, AHEPA University General Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece
| | | | - Georgia Kaiafa
- First Propaedeutic Department of Internal Medicine, AHEPA University General Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece
| | - Petros Papalexis
- Unit of Endocrinology, First Department of Internal Medicine, Laiko General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece
- Department of Biomedical Sciences, University of West Attica, 12243 Athens, Greece
| | - Adonis A. Protopapas
- First Propaedeutic Department of Internal Medicine, AHEPA University General Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece
| | - Eleftheria Ztriva
- First Propaedeutic Department of Internal Medicine, AHEPA University General Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece
| | - Varvara Fyntanidou
- Emergency Department, AHEPA University General Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece
| | - Christos Savopoulos
- First Propaedeutic Department of Internal Medicine, AHEPA University General Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece
| |
Collapse
|
133
|
He YF, Jiang ZG, Wu N, Bian N, Ren JL. Correlation between COVID-19 and hepatitis B: A systematic review. World J Gastroenterol 2022; 28:6599-6618. [PMID: 36569273 PMCID: PMC9782843 DOI: 10.3748/wjg.v28.i46.6599] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/11/2022] [Revised: 10/29/2022] [Accepted: 11/19/2022] [Indexed: 12/08/2022] Open
Abstract
BACKGROUND There is growing evidence that patients with coronavirus disease 2019 (COVID-19) frequently present with liver impairment. Hepatitis B virus (HBV) remains a major public health threat in current society. Both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and HBV can cause liver damage, and current findings on whether HBV infection increases disease severity in COVID-19 patients are inconsistent, and whether SARS-CoV-2 infection accelerates hepatitis B progression or leads to a worse prognosis in hepatitis B patients has not been adequately elucidated.
AIM To explore the complex relationship between COVID-19 and hepatitis B in order to inform the research and management of patients co-infected with SARS-CoV-2 and HBV.
METHODS An experienced information specialist searched the literature in the following online databases: PubMed, China National Knowledge Infrastructure, Google Scholar, Scopus, Wiley, Web of Science, Cochrane, and ScienceDirect. The literature published from December 2019 to September 1, 2022 was included in the search. We also searched medRxiv and bioRxiv for gray literature and manually scanned references of included articles. Articles reporting studies conducted in humans discussing hepatitis B and COVID-19 were included. We excluded duplicate publications. News reports, reports, and other gray literature were included if they contained quantifiable evidence (case reports, findings, and qualitative analysis). Some topics that included HBV or COVID-19 samples but did not have quantitative evidence were excluded from the review.
RESULTS A total of 57 studies were eligible and included in this review. They were from 11 countries, of which 33 (57.9%) were from China. Forty-two of the 57 studies reported abnormalities in liver enzymes, three mainly reported abnormalities in blood parameters, four indicated no significant liver function alterations, and another eight studies did not provide data on changes in liver function. Fifty-seven studies were retrospective and the total number of co-infections was 1932, the largest sample size was 7723, and the largest number of co-infections was 353. Most of the studies suggested an interaction between hepatitis B and COVID-19, while 12 studies clearly indicated no interaction between hepatitis B and COVID-19. Six of the 57 studies clearly reported HBV activation. Six studies were related to liver transplant patients.
CONCLUSION There is some association between COVID-19 and hepatitis B. Future high-quality randomized trials are needed to further elucidate the interaction between COVID-19 and hepatitis B.
Collapse
Affiliation(s)
- Yan-Fei He
- Health Management Center, The Sixth Medical Center, Chinese PLA General Hospital, Beijing 100048, China
| | - Zhi-Gang Jiang
- Department of Statistics, Zunyi Medical University, Guizhou 563006, Guizhou Province, China
| | - Ni Wu
- Health Management Center, The Sixth Medical Center, Chinese PLA General Hospital, Beijing 100048, China
| | - Ning Bian
- Health Management Center, The Sixth Medical Center, Chinese PLA General Hospital, Beijing 100048, China
| | - Jun-Lin Ren
- Department of Infection Control, The Sixth Medical Center, Chinese PLA General Hospital, Beijing 100048, China
| |
Collapse
|
134
|
Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy. Can J Gastroenterol Hepatol 2022; 2022:4291758. [PMID: 36531832 PMCID: PMC9754839 DOI: 10.1155/2022/4291758] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2022] [Revised: 10/31/2022] [Accepted: 11/12/2022] [Indexed: 12/13/2022] Open
Abstract
Following the SARS-CoV-2 outbreak and the subsequent development of the COVID-19 pandemic, organs such as the lungs, kidneys, liver, heart, and brain have been identified as priority organs. Liver diseases are considered a risk factor for high mortality from the COVID-19 pandemic. Besides, liver damage has been demonstrated in a substantial proportion of patients with COVID-19, especially those with severe clinical symptoms. Furthermore, antiviral medications, immunosuppressive drugs after liver transplantation, pre-existing hepatic diseases, and chronic liver diseases such as cirrhosis have also been implicated in SARS-CoV-2-induced liver injury. As a result, some precautions have been taken to prevent, monitor the virus, and avoid immunocompromised and susceptible individuals, such as liver and kidney transplant recipients, from being infected with SARS-CoV-2, thereby avoiding an increase in mortality. The purpose of this review was to examine the impairment caused by SARS-CoV-2 infection and the impact of drugs used during the pandemic on the mortality range and therefore the possibility of preventive measures in patients with liver disease.
Collapse
|
135
|
Saha L, Vij S, Rawat K. Liver injury induced by COVID 19 treatment - what do we know? World J Gastroenterol 2022; 28:6314-6327. [PMID: 36533104 PMCID: PMC9753058 DOI: 10.3748/wjg.v28.i45.6314] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/12/2022] [Revised: 10/07/2022] [Accepted: 11/17/2022] [Indexed: 12/02/2022] Open
Abstract
The severity of coronavirus disease 2019 (COVID-19) may be correlated with the risk of liver injury development. An increasing number of studies indicate that degrees of hepatotoxicity have been associated with using some medications in the management of COVID-19 patients. However, limited studies have systematically investigated the evidence of drug-induced liver injury (DILI) in COVID-19 patients. An increasing number of studies indicate that degrees of hepatotoxicity have been associated with using some of these medications in the management of COVID-19 patients. Significantly, it was relieved after the cessation of these agents. However, to our knowledge, no studies have systematically investigated the evidence of DILI in COVID-19 patients. In this review, we discussed the association between hepatotoxicity in COVID-19 patients and the drugs used in these patients and possible mechanisms of hepatotoxicity. The currently available evidence on the association of different therapeutic agents with hepatotoxicity in COVID-19 patient was systematically reviewed.
Collapse
Affiliation(s)
- Lekha Saha
- Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India
| | - Soumya Vij
- Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India
| | - Kajal Rawat
- Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India
| |
Collapse
|
136
|
Wang JY, Li TN, Zhou CL, Zhao J, Wang M, Wang Y, Jiang Y, Dong HN, Qi QR, Mu H. Clinical and immunological features of convalescent pediatric patients infected with the SARS-CoV-2 Omicron variant in Tianjin, China. Virol Sin 2022; 37:850-859. [PMID: 36328182 PMCID: PMC9621613 DOI: 10.1016/j.virs.2022.10.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2022] [Accepted: 10/27/2022] [Indexed: 11/06/2022] Open
Abstract
COVID-19 has spread surprisingly fast worldwide, and new variants continue to emerge. Recently, the World Health Organization acknowledged a new mutant strain "Omicron", with children were accounting for a growing share of COVID-19 cases compared with other mutant strains. However, the clinical and immunological characteristics of convalescent pediatric patients after Omicron infection were lacking. In this study, we comparatively analyzed the clinical data from pediatric patients with adult patients or healthy children and the effects of SARS-CoV-2 vaccine on the clinical and immune characteristics in convalescent pediatric patients. Our results indicated that convalescent pediatric patients had unique clinical and immune characteristics different from those of adult patients or healthy children, and SARS-CoV-2 vaccination significantly affected on the clinical and immune characteristics and the prevention of nucleic acid re-detectable positive (RP) in convalescent patients. Our study further deepens the understanding of the impact of Omicron on the long-term health of pediatric patients and provides a valuable reference for the prevention and treatment of children infected with Omicron.
Collapse
Affiliation(s)
- Jing-Yu Wang
- Department of Clinical Lab, Tianjin First Central Hospital, Tianjin, 300192, China
| | - Tian-Ning Li
- Department of Clinical Lab, Tianjin First Central Hospital, Tianjin, 300192, China
| | - Chun-Lei Zhou
- Department of Clinical Lab, Tianjin First Central Hospital, Tianjin, 300192, China
| | - Jie Zhao
- Department of Clinical Lab, Tianjin First Central Hospital, Tianjin, 300192, China
| | - Meng Wang
- Department of Clinical Lab, Tianjin First Central Hospital, Tianjin, 300192, China
| | - Yuan Wang
- Department of Clinical Lab, Tianjin First Central Hospital, Tianjin, 300192, China
| | - Yan Jiang
- Department of Clinical Lab, Tianjin First Central Hospital, Tianjin, 300192, China
| | - He-Nan Dong
- The First Central Clinical College, Tianjin Medical University, Tianjin, 300192, China
| | - Qian-Ru Qi
- Department of Clinical Lab, Tianjin Children's Hospital, Tianjin, 300074, China
| | - Hong Mu
- Department of Clinical Lab, Tianjin First Central Hospital, Tianjin, 300192, China,Corresponding author
| |
Collapse
|
137
|
Elghannam MT, Hassanien MH, Ameen YA, ELattar GM, ELRay AA, Turky EA, ELTalkawy MD. COVID-19 and liver diseases. EGYPTIAN LIVER JOURNAL 2022; 12:43. [PMID: 35880136 PMCID: PMC9301896 DOI: 10.1186/s43066-022-00202-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Accepted: 07/06/2022] [Indexed: 12/15/2022] Open
Abstract
Coronavirus causes an outbreak of viral pneumonia that spread throughout the world. Liver injury is becoming more widely recognized as a component of the clinical picture of COVID-19 infection. Hepatitis with serum ALT elevation has been reported in up to half of patients. Patients with CLD were at a higher risk of decompensation with liver failure, hospitalization, and mortality. The percentage of acute liver injury (ALI) varied from 5 to 28%. COVID-19 hinders HCV elimination by 2030. It is recommended to continue treatment of chronic HCV and chronic HBV if already receiving treatment. Consider using antiviral therapy to prevent viral flare-ups in patients with occult or resolved HBV and COVID-19 who are receiving immunosuppressive agents. Patients with AIH do not have an increased risk of adverse outcomes even in high-risk areas. There is an association between MAFLD and disease progression. Patients with any type of cancer are at a higher risk of infection and are more likely to develop more severe clinical outcomes. Most societies advise against immunosuppressant modifications in patients with mild COVID-19, whereas in rare cases such as severe lymphopenia, worsening pneumonia, or bacterial or fungal superinfection, reduction or discontinuation of antiproliferative agents and lymphocyte-depleting therapies has been suggested.
Collapse
|
138
|
Gopaul CD, Ventour D, Thomas D. Laboratory predictors for COVID-19 Intensive Care Unit admissions in Trinidad and Tobago. DIALOGUES IN HEALTH 2022; 1:100022. [PMID: 36785629 PMCID: PMC9170592 DOI: 10.1016/j.dialog.2022.100022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/25/2022] [Revised: 05/20/2022] [Accepted: 05/31/2022] [Indexed: 01/08/2023]
Abstract
Understanding symptoms associated with COVID-19 cases requiring intensive care unit(ICU) attention is important in management of the life-threatening cases of the disease. This study aimed to determine laboratory indicators of ICU admission for COVID-19 patients. For this retrospective chart review study, data from 116 patients(ICU, n = 18, Non-ICU, n = 98) with confirmed SARS-CoV-2, managed at two hospitals in Trinidad and Tobago, from March 12th to April 12th 2020, were analyzed. The median age of non-ICU patients was 59.0(IQR = 23.5) years; ICU patients had a median age of 62.5(IR = 17.5). From univariate analysis, laboratory indicators significantly associated with ICU admission included WBC(P = 0.037), lymphocyte(P = 0.016), LDH(P = 0.002), AST(P = 0.005) and CRP(P = 0.0001). However, multivariate analysis including WBC, neutrophil, lymphocyte, PLT, AST, LDH, ALT and CRP indicated that only AST was associated with high odds of ICU admission(OR 0.002, 95% CI 0.000-0.004, P = 0.017). Statistically significant AUC were obtained for neutrophil(AUC = 0.704, P = 0.007), CRP (AUC = 0.81, p = 0.00) and LDH(AUC = 0.766, P = 0.00) and AST (AUC = 0.729, P = 0.003). The findings indicate that neutrophils, AST and LDH's ROC curves are good tests, CRP curve is a very good test, but lymphocyte curve is a poor test, in determining COVID-19 patients for ICU admission. Neutrophil, AST, LDH and CRP are suitable predictors of COVID-19 patients that should receive intensive unit care. The study provides significant insights into laboratory parameters that can be used to predict COVID-19 severity and important considerations for healthcare providers in making evidence-based decisions regarding COVID-19 patient management, especially in the context of limited ICU facilities. This study was not funded.
Collapse
Affiliation(s)
- Chavin D. Gopaul
- North Central Regional Health Authority, Champs Fleurs, Trinidad and Tobago
| | - Dale Ventour
- Faculty of Medical Sciences, University of the West Indies, St. Augustine, Trinidad and Tobago
| | - Davlin Thomas
- North Central Regional Health Authority, Champs Fleurs, Trinidad and Tobago
| |
Collapse
|
139
|
Pal M, Muinao T, Parihar A, Roy DK, Boruah HPD, Mahindroo N, Khan R. Biosensors based detection of novel biomarkers associated with COVID-19: Current progress and future promise. BIOSENSORS & BIOELECTRONICS: X 2022; 12:100281. [PMID: 36405494 PMCID: PMC9661549 DOI: 10.1016/j.biosx.2022.100281] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/04/2022] [Revised: 11/02/2022] [Accepted: 11/03/2022] [Indexed: 11/16/2022]
Abstract
The pandemic situation of COVID-19 has caused global alarm in health care, devastating loss of lives, strangled economy, and paralysis of normal livelihood. The high inter-individual transmission rate created havoc in the global community. Although tremendous efforts are pitching in from across the globe to understand this disease, the clinical features seemed to have a wide range including fever, cough, and fatigue are the prominent features. Congestion, rhinorrhea, sore throat, and diarrhea are other less common features observed. The challenge of this disease lies in the difficulty in maneuvering the clinical course causing severe complications. One of the major causative factors for multi-organ failure in patients with severe COVID-19 complications is systemic vasculitis and cytokine-mediated coagulation disorders. Hence, effective markers trailing the disease severity and disease prognosis are urgently required for prompt medical treatment. In this review article, we have emphasized currently identified inflammatory, hematological, immunological, and biochemical biomarkers of COVID-19. We also discussed currently available biosensors for the detection of COVID-19-associated biomarkers & risk factors and the detection methods as well as their performances. These could be effective tools for rapid and more promising diagnoses in the current pandemic situation. Effective biomarkers and their rapid, scalable, & sensitive detection might be beneficial for the prevention of serious complications and the clinical management of the disease.
Collapse
Affiliation(s)
- Mintu Pal
- Biotechnology Group, Biological Sciences and Technology Division, CSIR-North East Institute of Science and Technology (NEIST), Academy of Scientific & Innovative Research (AcSIR), CSIR-NEIST Campus, Jorhat, Assam, 785006, India
- Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bathinda, Punjab, 151001, India
| | - Thingreila Muinao
- Biotechnology Group, Biological Sciences and Technology Division, CSIR-North East Institute of Science and Technology (NEIST), Academy of Scientific & Innovative Research (AcSIR), CSIR-NEIST Campus, Jorhat, Assam, 785006, India
| | - Arpana Parihar
- CSIR-Advanced Materials and Processes Research Institute (AMPRI), Hoshangabad Road, Bhopal, 462026, MP, India
| | - Dilip Kumar Roy
- Department of Pharmaceutical Technology, JIS University, Kolkata, 700109, India
| | - Hari Prasanna Deka Boruah
- Biotechnology Group, Biological Sciences and Technology Division, CSIR-North East Institute of Science and Technology (NEIST), Academy of Scientific & Innovative Research (AcSIR), CSIR-NEIST Campus, Jorhat, Assam, 785006, India
- Government Model College, Kaziranga, Golaghat, Assam, 785609, India
| | - Neeraj Mahindroo
- School of Pharmacy, Dr. Vishwanath Karad MIT World Peace University, Pune, Maharashtra, 411038, India
| | - Raju Khan
- CSIR-Advanced Materials and Processes Research Institute (AMPRI), Hoshangabad Road, Bhopal, 462026, MP, India
| |
Collapse
|
140
|
Li X, Wang W, Yan S, Zhao W, Xiong H, Bao C, Chen J, Yue Y, Su Y, Zhang C. Drug-induced liver injury in COVID-19 treatment: Incidence, mechanisms and clinical management. Front Pharmacol 2022; 13:1019487. [PMID: 36518661 PMCID: PMC9742434 DOI: 10.3389/fphar.2022.1019487] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2022] [Accepted: 11/14/2022] [Indexed: 07/21/2023] Open
Abstract
The COVID-19 outbreak triggered a serious and potentially lethal pandemic, resulting in massive health and economic losses worldwide. The most common clinical manifestations of COVID-19 patients are pneumonia and acute respiratory distress syndrome, with a variety of complications. Multiple organ failure and damage, ultimately leading to patient death, are possible as a result of medication combinations, and this is exemplified by DILI. We hope to summarize DILI caused by the antiviral drugs favipiravir, remdesivir, lopinavir/ritonavir, and hydroxychloroquine in COVID-19 patients in this review. The incidence of liver injury in the treatment of COVID-19 patients was searched on PubMed to investigate DILI cases. The cumulative prevalence of acute liver injury was 23.7% (16.1%-33.1%). We discuss the frequency of these events, potential mechanisms, and new insights into surveillance strategies. Furthermore, we also describe medication recommendations aimed at preserving DILI caused by treatment in COVID-19 patients.
Collapse
Affiliation(s)
- Xichuan Li
- Tianjin Key Laboratory of Animal and Plant Resistance, College of Life Sciences, Tianjin Normal University, Tianjin, China
| | - Wanting Wang
- Department of Colorectal Surgery, Tianjin Institute of Coloproctology, The Institute of Translational Medicine, Tianjin Union Medical Center of Nankai University, Tianjin, China
- Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Suying Yan
- Department of Colorectal Surgery, Tianjin Institute of Coloproctology, The Institute of Translational Medicine, Tianjin Union Medical Center of Nankai University, Tianjin, China
- Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Weipeng Zhao
- Department of Breast Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
| | - Hui Xiong
- School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China
| | - Cuiping Bao
- Departments of Radiology, Tianjin Union Medical Center, Tianjin, China
| | - Jinqian Chen
- Departments of Pharmacy, NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital, Tianjin, China
| | - Yuan Yue
- Tianjin Key Laboratory of Animal and Plant Resistance, College of Life Sciences, Tianjin Normal University, Tianjin, China
| | - Yanjun Su
- Department of Lung Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
| | - Chunze Zhang
- Department of Colorectal Surgery, Tianjin Institute of Coloproctology, The Institute of Translational Medicine, Tianjin Union Medical Center of Nankai University, Tianjin, China
| |
Collapse
|
141
|
Yu SY, Xie JR, Luo JJ, Lu HP, Xu L, Wang JJ, Chen XQ. Liver test abnormalities in asymptomatic and mild COVID-19 patients and their association with viral shedding time. World J Hepatol 2022; 14:1953-1963. [PMID: 36483605 PMCID: PMC9724107 DOI: 10.4254/wjh.v14.i11.1953] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/01/2022] [Revised: 10/25/2022] [Accepted: 11/21/2022] [Indexed: 11/24/2022] Open
Abstract
BACKGROUND Asymptomatic infections and mild symptoms are common in patients infected with the Omicron variant, and data on liver test abnormalities are rare.
AIM To evaluated the clinical characteristics of asymptomatic and mild coronavirus disease 2019 (COVID-19) patients with abnormal liver test results.
METHODS This retrospective study included 661 laboratory-confirmed asymptomatic and mild COVID-19 patients who were treated in two makeshift hospitals in Ningbo from April 5, 2022 to April 29, 2022. Clinical information and viral shedding time were collected, and univariate and multivariate logistic regression models were performed in statistical analyses.
RESULTS Of the 661 patients, 83 (12.6%) had liver test abnormalities, and 6 (0.9%) had liver injuries. Abnormal liver tests revealed a reliable correlation with a history of liver disease (P < 0.001) and a potential correlation with male sex and obesity (P < 0.05). Elevated alanine aminotransferase was reliably associated with obesity (P < 0.05) and a history of liver disease (P < 0.001). Elevated aspartate transaminase (AST) was reliably correlated with a history of liver disease (P < 0.001), and potentially correlated with age over 30 years (P < 0.05). There was a reliable correlation between AST ≥ 2× the upper limit of normal and a longer viral shedding time, especially in mild cases.
CONCLUSION Obesity and a history of liver disease are risk factors for liver test abnormalities. Being male and an older age are potential risk factors. Attention should be given to liver tests in asymptomatic and mild COVID-19 patients, which has crucial clinical significance for evaluating the viral shedding time.
Collapse
Affiliation(s)
- Si-Yi Yu
- Department of Gastroenterology, Ningbo First Hospital, Ningbo 315010, Zhejiang Province, China
| | - Jia-Rong Xie
- Department of Gastroenterology, Ningbo First Hospital, Ningbo 315010, Zhejiang Province, China
| | - Jun-Jun Luo
- Department of Cardiology, Ningbo First Hospital, Ningbo 315010, Zhejiang Province, China
| | - Hong-Peng Lu
- Department of Gastroenterology, Ningbo First Hospital, Ningbo 315010, Zhejiang Province, China
| | - Lei Xu
- Department of Gastroenterology, Ningbo First Hospital, Ningbo 315010, Zhejiang Province, China
| | - Jun-Jie Wang
- Department of Information Technology, Ningbo First Hospital, Ningbo 315010, Zhejiang Province, China
| | - Xue-Qin Chen
- Department of Traditional Medicine, Ningbo First Hospital, Ningbo 315010, Zhejiang Province, China
| |
Collapse
|
142
|
Hanif FM, Majid Z, Ahmed S, Luck NH, Mubarak M. Hepatic manifestations of coronavirus disease 2019 infection: Clinical and laboratory perspective. World J Virol 2022; 11:453-466. [PMID: 36483109 PMCID: PMC9724207 DOI: 10.5501/wjv.v11.i6.453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/12/2022] [Revised: 10/17/2022] [Accepted: 11/07/2022] [Indexed: 11/23/2022] Open
Abstract
The novel coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2, has become a global challenge of unprecedented nature since December 2019. Although most patients with COVID-19 exhibit mild clinical manifestations and upper respiratory tract involvement, in approximately 5%-10% of patients, the disease is severe and involves multiple organs, leading to multi-organ dysfunction and failure. The liver and gastrointestinal tract are also frequently involved in COVID-19. In the context of liver involvement in patients with COVID-19, many key aspects need to be addressed in both native and transplanted organs. This review focuses on the clinical presentations and laboratory abnormalities of liver function tests in patients with COVID-19 with no prior liver disease, patients with pre-existing liver diseases and liver transplant recipients. A brief overview of the history of COVID-19 and etiopathogenesis of the liver injury will also be described as a prelude to better understanding the above aspects.
Collapse
Affiliation(s)
- Farina M Hanif
- Department of Hepatogastroenterology, Sindh Institute of Urology and Transplantation, Karachi 74200, Sindh, Pakistan
| | - Zain Majid
- Department of Hepatogastroenterology, Sindh Institute of Urology and Transplantation, Karachi 74200, Sindh, Pakistan
| | - Shoaib Ahmed
- Department of Hepatogastroenterology, Sindh Institute of Urology and Transplantation, Karachi 74200, Sindh, Pakistan
| | - Nasir H Luck
- Department of Hepatogastroenterology, Sindh Institute of Urology and Transplantation, Karachi 74200, Sindh, Pakistan
| | - Muhammed Mubarak
- Department of Pathology, Sindh Institute of Urology and Transplantation, Karachi 74200, Sindh, Pakistan
| |
Collapse
|
143
|
Hardy YO, Libhaber E, Ofori E, Amenuke D, Kontoh SA, Dankwah JA, Larsen‐Reindorf R, Otu‐Ansah C, Hutton‐Mensah K, Dadson E, Adamu S, Akyerekoh K, Sarfo FS, Nkum B. Clinical and laboratory profile and outcomes of hospitalized COVID-19 patients with type 2 diabetes mellitus in Ghana - A single-center study. Endocrinol Diabetes Metab 2022; 6:e391. [PMID: 36426913 PMCID: PMC9836241 DOI: 10.1002/edm2.391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2022] [Revised: 10/26/2022] [Accepted: 11/05/2022] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND In sub-Saharan Africa and particularly in Ghana, there is scarcity of published literature specifically on the impact of DM on outcomes in COVID-19 patients. Based on the difference in genetic makeup and demographic patterns in Africans compared to the Western world and with the rising burden of DM and other non-communicable diseases in Ghana there is a need to define the impact DM has on persons with COVID-19. This would ensure adequate risk stratification and surveillance for such patients as well as appropriate scale up of therapeutic management if needed. AIMS This single-center study describes the clinical and laboratory profile and outcomes of COVID-19 in-patients with type 2 diabetes mellitus (DM) in Ghana. MATERIALS AND METHODS Retrospective analysis was undertaken of the medical records of adults with COVID-19 hospitalized at a facility in Ghana from March to October 2020. Clinical, laboratory and radiological data and outcomes were analysed. Comparisons between COVID-19 patients with DM and non-diabetics were done with an independent t-test or a Mann-Whitney test when normality was not attained. Odds ratios (95% CI) were calculated using univariate logistic regression. RESULTS Out of 175 COVID-19 patients, 64 (36.6%) had DM. Overall mean age was 55.9 ± 18.3 years; DM patients were older compared to non-diabetics (61.1 ± 12.8 vs. 53.0 ± 20.2 years, p = .049). Compared to non-diabetics, diabetics were more likely to have higher blood glucose at presentation, have hypertension, be on angiotensin 2 receptor blockers [OR, 95% CI 3.3 (1.6-6.7)] and angiotensin converting enzyme inhibitors [OR, 95% CI 3.1 (1.3-7.4)]; and be HIV negative (p < .05). Although the values were normal, diabetics had a higher platelet count but decreased lymphocytes, aspartate transaminase and alkaline phosphatase compared to non-diabetics (p < .05). There was no difference in clinical symptoms, severity or mortality between the two groups. DISCUSSION The clinical profile of patients studied are similar to prior studies. However the outcome of this study showed that DM was not associated with worse clinical severity and in-hospital mortality. This could have been due to majority of DM patients in this study having relatively good blood glucose control on admission. Secondly, DM alone may not be a risk factor for mortality. Rather its concurrent existence with multiple co-morbidities (especially cardiovascular co-morbidities which may predispose to pro-inflammatory and pro-thrombotic states) may be driving the rise in severity and mortality risks reported in other studies. Furthermore, this study was conducted among an African population and Africa has been shown to be generally less severely hit by the COVID-19 pandemic compared to other regions outside the continent. This has been postulated to be due, among other factors, to inherent protective mechanisms in Africans due to early and repeated exposure to parasitic and other organisms resulting in a robust innate immunity. CONCLUSIONS This study suggested that DM was not associated with more severe clinical symptoms or worse outcomes among hospitalized COVID-19 patients. Despite this, it is important that DM patients adhere to their therapy, observe the COVID-19 containment protocols and are prioritized in the administration of the COVID-19 vaccines. STUDY HIGHLIGHTS In this retrospective, single-centre study on the clinical and laboratory profile and outcome of hospitalized DM patients with COVID-19, patients with DM did not have a more severe clinical profile or worse outcomes. They were, however, significantly older, more likely to have higher admission blood glucose, have hypertension, be on angiotensin 2 receptor blockers and angiotensin converting enzyme inhibitors; and be HIV negative compared to the cohort without DM. DM patients should be a priority group for the COVID-19 vaccines.
Collapse
Affiliation(s)
- Yasmine Oladele Hardy
- Directorate of Medicine, Komfo Anokye Teaching HospitalKumasiGhana,School of Medical SciencesKwame Nkrumah University of Science and TechnologyKumasiGhana
| | - Elena Libhaber
- School of Clinical Medicine and Health Sciences Research Office, Faculty of Health SciencesUniversity of the WitwatersrandJohannesburgSouth Africa
| | - Emmanuel Ofori
- Directorate of Medicine, Komfo Anokye Teaching HospitalKumasiGhana
| | - Divine Aseye Yao Amenuke
- Directorate of Medicine, Komfo Anokye Teaching HospitalKumasiGhana,School of Medical SciencesKwame Nkrumah University of Science and TechnologyKumasiGhana
| | - Samuel Amoabeng Kontoh
- Department of Pharmacy Practice, College of Health SciencesKwame Nkrumah University of Science and TechnologyKumasiGhana
| | - James Amoah Dankwah
- Directorate of Medicine, Komfo Anokye Teaching HospitalKumasiGhana,School of Medical SciencesKwame Nkrumah University of Science and TechnologyKumasiGhana
| | | | - Caleb Otu‐Ansah
- Directorate of Psychiatry, Komfo Anokye Teaching HospitalKumasiGhana
| | | | - Ebenezer Dadson
- Directorate of Radiology, Komfo Anokye Teaching HospitalKumasiGhana
| | - Sheila Adamu
- Directorate of Medicine, Komfo Anokye Teaching HospitalKumasiGhana,School of Medical SciencesKwame Nkrumah University of Science and TechnologyKumasiGhana
| | - Kofi Akyerekoh
- Directorate of Medicine, Komfo Anokye Teaching HospitalKumasiGhana
| | - Fred Stephen Sarfo
- Directorate of Medicine, Komfo Anokye Teaching HospitalKumasiGhana,School of Medical SciencesKwame Nkrumah University of Science and TechnologyKumasiGhana
| | - Bernard Nkum
- Directorate of Medicine, Komfo Anokye Teaching HospitalKumasiGhana,School of Medical SciencesKwame Nkrumah University of Science and TechnologyKumasiGhana
| |
Collapse
|
144
|
Mihai N, Lazar M, Tiliscan C, Barbu EC, Chitu CE, Stratan L, Ganea OA, Arama SS, Ion DA, Arama V. Predictors of Liver Injury in Hospitalized Patients with SARS-CoV-2 Infection. Medicina (B Aires) 2022; 58:medicina58121714. [PMID: 36556915 PMCID: PMC9786677 DOI: 10.3390/medicina58121714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2022] [Revised: 11/15/2022] [Accepted: 11/21/2022] [Indexed: 11/24/2022] Open
Abstract
Background and Objectives: SARS-CoV-2 infection is frequently associated with pneumonia but has a broad tissue tropism also leading to systemic complications (hematologic, gastro-intestinal, cardiac, neurologic, etc.). In this study, we aim to evaluate the impact of COVID-19 infection on the liver and to identify the risk factors/predictors for liver injury at admission to the hospital. Materials and Methods: We performed a retrospective cohort study on 249 patients, divided into two Group A (157 patients with liver involvement) and Group B (92 patients without liver involvement). We recorded demographic and lifestyle parameters, anthropometric parameters, comorbidities, clinical parameters, inflammation markers, complete blood count, coagulation, and biochemical parameters. Lung parenchyma, liver dimensions, and morphology were evaluated by computer tomography (CT) scans. Results: Patients with liver involvement had higher heart and respiratory rates, lower oxygen saturation (SO2), and necessitated higher oxygen flow at admittance. We found higher serum levels of C-reactive protein, fibrinogen, ferritin, creatine kinase, lactate dehydrogenase (LDH), serum triglycerides, and lower values for serum albumin in Group A patients. The patients with liver involvement presented more extensive lung injury with higher percentages of alveolar, mixed, and interstitial lesions, an increase in liver dimensions, and lower density ranges for the liver parenchyma. The patients presented hepatocytolytic involvement in 26 cases (10.4% from the entire study population), cholestatic involvement in 63 cases (37.7% from the entire study population), and mixed liver involvement in 68 cases (37.7% from the entire study population). Conclusions: Liver involvement in COVID-19 patients is frequent, usually mild, and occurs mostly in male patients over 50 years old. Cholestatic and mixed liver injuries are more frequent than hepatocytolytic injuries. The severity of lung injury evaluated by CT scan, increased values of inflammatory markers, LDH, and low values of SO2 can be considered risk factors/predictors for liver injury at admission to the hospital.
Collapse
Affiliation(s)
- Nicoleta Mihai
- Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu Street, 020021 Bucharest, Romania
- “Prof. Dr. Matei Bals” National Institute for Infectious Diseases, 1 Dr. Grozovici Street, 021105 Bucharest, Romania
| | - Mihai Lazar
- Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu Street, 020021 Bucharest, Romania
- “Prof. Dr. Matei Bals” National Institute for Infectious Diseases, 1 Dr. Grozovici Street, 021105 Bucharest, Romania
- Correspondence: (M.L.); (C.T.)
| | - Catalin Tiliscan
- Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu Street, 020021 Bucharest, Romania
- “Prof. Dr. Matei Bals” National Institute for Infectious Diseases, 1 Dr. Grozovici Street, 021105 Bucharest, Romania
- Correspondence: (M.L.); (C.T.)
| | - Ecaterina Constanta Barbu
- Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu Street, 020021 Bucharest, Romania
| | - Cristina Emilia Chitu
- Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu Street, 020021 Bucharest, Romania
| | - Laurentiu Stratan
- Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu Street, 020021 Bucharest, Romania
| | - Oana Alexandra Ganea
- Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu Street, 020021 Bucharest, Romania
- “Prof. Dr. Matei Bals” National Institute for Infectious Diseases, 1 Dr. Grozovici Street, 021105 Bucharest, Romania
| | - Sorin Stefan Arama
- Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu Street, 020021 Bucharest, Romania
| | - Daniela Adriana Ion
- Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu Street, 020021 Bucharest, Romania
| | - Victoria Arama
- Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu Street, 020021 Bucharest, Romania
- “Prof. Dr. Matei Bals” National Institute for Infectious Diseases, 1 Dr. Grozovici Street, 021105 Bucharest, Romania
| |
Collapse
|
145
|
Zhang J, Zhao D, Hu J, Huang X, Gu Q, Tao Z. Hepatic dysfunctions in COVID-19 patients infected by the omicron variant of SARS-CoV-2. Front Public Health 2022; 10:1049006. [PMID: 36466505 PMCID: PMC9716022 DOI: 10.3389/fpubh.2022.1049006] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Accepted: 10/24/2022] [Indexed: 11/19/2022] Open
Abstract
Background Presently, the omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) dominates amid the coronavirus disease 2019 (COVID-19) pandemic, but its clinical characteristics with intrinsic severity and organ tropism remain understudied. Methods We reported 1,001 mild COVID-19 patients that were infected with the omicron variant of SARS-CoV-2 and hospitalized in China from February to June 2022, including their demographic information, medical/immunization history, clinical symptom, and hematological profile. Patients with one-, two- and three-dose vaccination were compared to assess the vaccine effectiveness. Importantly, liver damage caused by the omicron variant infection was evaluated, in comparison to that caused by the wild-type or the delta variant SARS-CoV-2 infection. Results For the reported COVID-19 patients infected by the omicron variant of SARS-CoV-2, their median age was 36.0 [interquartile range (IQR): 26.0-50.0] and 49.7% were female. Hypertension, diabetes, and bronchitis were the leading comorbidities, and asymptomatic patients took up a major portion (61.2%). While most hematological parameters revealed the alleviated pathogenicity, full vaccination or booster shot showed effective protection against clinical severity. Furthermore, liver damages caused by viral infection of the omicron variant were largely attenuated when compared to those by infection of the wild-type or the delta variant SARS-CoV-2. Conclusions Our results supported that the viremic effect of the omicron variant tended to be modest, while the liver damage caused by this strain became milder than the previous circulating variants.
Collapse
Affiliation(s)
- Jianguo Zhang
- Department of Emergency Medicine, The Affiliated Hospital of Jiangsu University, Zhenjiang, China
| | - Daguo Zhao
- Department of Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Jianhui Hu
- Department of Laboratory Medicine, Zhenjiang Hospital Affiliated to Nanjing University of Chinese Medicine, Zhenjiang Hospital of Traditional Chinese Medicine, Zhenjiang, China
| | - Xing Huang
- Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Qingqing Gu
- Department of Infectious Diseases, The Affiliated Hospital of Kangda College of Nanjing Medical University, The Fourth People's Hospital of Lianyungang, Lianyungang, China
| | - Zhimin Tao
- Department of Emergency Medicine, The Affiliated Hospital of Jiangsu University, Zhenjiang, China,Jiangsu Province Key Laboratory of Medical Science and Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, China,*Correspondence: Zhimin Tao
| |
Collapse
|
146
|
Cooper KM, Colletta A, Asirwatham AM, Moore Simas TA, Devuni D. COVID-19 associated liver injury: A general review with special consideration of pregnancy and obstetric outcomes. World J Gastroenterol 2022; 28:6017-6033. [PMID: 36405386 PMCID: PMC9669825 DOI: 10.3748/wjg.v28.i42.6017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/12/2022] [Revised: 10/24/2022] [Accepted: 10/27/2022] [Indexed: 11/15/2022] Open
Abstract
Liver injury is an increasingly recognized extra-pulmonary manifestation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Coronavirus disease 2019 (COVID-19) associated liver injury (COVALI) is a clinical syndrome encompassing all patients with biochemical liver injury identified in the setting of SARS-CoV-2 infection. Despite profound clinical implications, its pathophysiology is poorly understood. Unfortunately, most information on COVALI is derived from the general population and may not be applicable to individuals under-represented in research, including pregnant individuals. This manuscript reviews: Clinical features of COVALI, leading theories of COVALI, and existing literature on COVALI during pregnancy, a topic not widely explored in the literature. Ultimately, we synthesized data from the general and perinatal populations that demonstrates COVALI to be a hepatocellular transaminitis that is likely induced by systemic inflammation and that is strongly associated with disease severity and poorer clinical outcome, and offered perspective on approaching transaminitis in the potentially COVID-19 positive patient in the obstetric setting.
Collapse
Affiliation(s)
- Katherine M. Cooper
- Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01605, United States
| | - Alessandro Colletta
- Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01605, United States
| | - Alison M. Asirwatham
- Department of Obstetrics and Gynecology, University of Massachusetts Chan Medical School, Worcester, MA 01605, United States
| | - Tiffany A. Moore Simas
- Department of Obstetrics and Gynecology, University of Massachusetts Chan Medical School, Worcester, MA 01605, United States
- Departments of Pediatrics, Psychiatry, and Population & Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA 01605, United States
| | - Deepika Devuni
- Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01605, United States
- Division of Gastroenterology and Hepatology, University of Massachusetts Chan Medical School, Worcester, MA 1605, United States
| |
Collapse
|
147
|
Al-Shammari AH, Ali Shahadha MA. The effect of Favipiravir on liver enzyme among patients with mild to moderate COVID-19 infection: A prospective cohort study. JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY = JOURNAL DE LA THERAPEUTIQUE DES POPULATIONS ET DE LA PHARMACOLOGIE CLINIQUE 2022; 29:e46-e54. [PMID: 36398597 DOI: 10.15586/jptcp.2022.967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 09/11/2022] [Accepted: 10/11/2022] [Indexed: 06/16/2023]
Abstract
Teratogenicity and hyperuricemia are considered as the major adverse effects of favipiravir, but less is known about other possible side effects which includes drug-induced liver damage and renal injury. In the current research, assessment of favipiravir-induced liver injury was performed by evaluating liver enzymes among patients with mild to moderate COVID-19 infection. A prospective cohort study was conducted on 66 patients diagnosed with mild to moderate COVID-19 infection who were treated with favipiravir for 5 days. During this period, a baseline assessment of liver enzymes (aspartate aminotransferase - AST, alanine transaminase - ALT and alkaline phosphatase - ALP) in addition to bilirubin before initiation of therapy and after 1 day of completion of therapy were carried out. The comparison of all measured parameters among all patients before and after receiving the treatment showed that non-significant differences were obtained in their levels. It was noticed that COVID-19 patients demonstrated high AST levels in which only 16 patients out of the all-subjected cases (66 patients) had AST levels of less than 45 U/L whereas the majority of patients showed normal ALT, ALP, and bilirubin levels. It was concluded that 5 days administration of favipiravir in mild to moderate COVID-19 patients who had no previous liver diseases did not affect the liver enzymes significantly and only transient elevations were occurred.
Collapse
|
148
|
Liu X, Tian X, Ma Z, Chen J, Huang Q, Gao P, Zhang C. Efficacy and safety of glycyrrhizic acid preparation treating comorbid liver injury in COVID-19: A systematic review. Front Pharmacol 2022; 13:1003697. [PMID: 36408213 PMCID: PMC9669476 DOI: 10.3389/fphar.2022.1003697] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2022] [Accepted: 10/18/2022] [Indexed: 10/12/2023] Open
Abstract
Background: No specific drug for COVID-19 has been found, and many studies have found that different degrees of liver injury often occurred after infection with COVID-19. Glycyrrhizic acid preparation (GAP) has been frequently used clinically, often combined with conventional treatments such as antiviral therapy, to improve the prognosis of COVID-19 and patients' liver function. Aims: To critically review and analyze clinical evidence on the efficacy and safety of GAP in the treatment of COVID-19 alone and COVID-19 with comorbid liver injury. Methods: A systematic literature review was performed following a sensitive searching strategy that examines all articles published in "WHO COVID-19 Research Database," "Cochrane Library," "VIP," "CNKI," "Wanfang," and "CBM" from 2020 to July 2022. Articles were evaluated by peer reviewers and used Joanna Briggs Institute (JBI) critical appraisal tools to complete the assessment of the risk of bias. Results: Ten clinical studies were finally included, involving 598 patients with COVID-19, of whom 189 were confirmed to be with comorbid liver injury. The main GAPs used are diammonium glycyrrhizinate and magnesium isoglycyrrhizinate, which have shown efficacy in improving liver function, inhibiting inflammation, and enhancing immunity. We are still seeking more related research. Conclusion: Glycyrrhizic acid preparations (mainly diammonium glycyrrhizinate and magnesium isoglycyrrhizinate) have a considerable clinical effect on improving liver function in patients with COVID-19 alone or with comorbid liver injury. Further studies on the use of GAP in the treatment of COVID-19 with comorbid liver injury and its mechanism are still needed. Systematic Review Registration: [www.crd.york.ac.uk/prospero], identifier [CRD42021234647].
Collapse
Affiliation(s)
- Xu Liu
- Department of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Xia Tian
- Department of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Zhipeng Ma
- Department of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Jiali Chen
- Department of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Qingsong Huang
- Department of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Peiyang Gao
- Department of Critical Care Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Chuantao Zhang
- Department of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
| |
Collapse
|
149
|
Ferreira AI, Sarmento MH, Cotter J. Predictors of clinical outcomes of hospitalized patients with Covid-19: focusing on pre-existing liver disease. Intern Emerg Med 2022; 17:2209-2217. [PMID: 35904701 PMCID: PMC9336142 DOI: 10.1007/s11739-022-03044-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/29/2022] [Accepted: 06/23/2022] [Indexed: 01/08/2023]
Abstract
Chronic liver disease is associated with immune system dysfunction, which can lead to a greater risk of infections. Our goal was to assess the impact of chronic liver disease in Covid-19 outcome in hospitalized patients and to identify predictors of the infection's severity. A retrospective case-control study of adult patients hospitalized in Hospital da Senhora da Oliveira-Guimarães, between March 15th 2020 and March 15th 2021, was performed. Demographic factors, clinical and biochemical data were analyzed, as well as the need for oxygen therapy, non-invasive or mechanical ventilation, admission in the intensive care unit and mortality. A total of 336 patients were included, 168 with and 168 without chronic liver disease, with similar comorbidities and pulmonary involvement. Patients with chronic liver disease had a lower percentage of need for oxygen therapy. Regardless of the presence of chronic liver disease, older age, a previously diagnosed pulmonary disease or cardiac condition and more than 25% pulmonary involvement were associated with increased mortality. The need for non-invasive ventilation was higher if the patient was obese, had a previously diagnosed pulmonary disease or had a higher percentage of lung parenchyma involvement. The need for admission in the intensive care unit was associated with obesity and a greater than 25% pulmonary involvement. Chronic liver disease had no impact on Covid-19 severity. Regardless of the presence of chronic liver disease, obesity had an important role in all outcomes except mortality. A higher percentage of lung parenchyma involvement was associated with worst outcomes.
Collapse
Affiliation(s)
- Ana Isabel Ferreira
- Department of Gastroenterology, Hospital Senhora da Oliveira-Guimarães, Rua dos Cutileiros 114, Creixomil, 4835-044, Guimarães, Portugal.
| | - Maria Helena Sarmento
- Department of Internal Medicine, Hospital Senhora da Oliveira-Guimarães, Rua dos Cutileiros 114, Creixomil, 4835-044, Guimarães, Portugal
| | - Jorge Cotter
- Department of Internal Medicine, Hospital Senhora da Oliveira-Guimarães, Rua dos Cutileiros 114, Creixomil, 4835-044, Guimarães, Portugal
| |
Collapse
|
150
|
Bakhtiyarova KS, Papoyan AO, Alekseev AV, Vishnyakov DS, Grazhdankin AA, Gilyazova IR, Nasibullina AK, Kislitsyna MV, Vakhitova AA, Zolotukhin KN, Kabirov IR, Pavlov VN. Early Changes in Clinical and Laboratory Parameters in Patients Died of COVID-19. MESSENGER OF ANESTHESIOLOGY AND RESUSCITATION 2022. [DOI: 10.21292/2078-5658-2022-19-5-55-62] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/18/2023]
Abstract
261,435,768 COVID-19 infections were detected worldwide, of them 5,207,634 deaths were registered. Identifying markers of the patient severity early in the course of the disease can facilitate the assessment of the risk of adverse outcome.The objective: To compare values of laboratory parameters and their changes during treatment of patients with a complicated course of COVID-19 infection.Subjects and Methods. 56 patients were included in the study, all of them were hospitalized to COVID Hospital of the Clinic of Bashkir State Medical University, Russian Ministry of Health, from September 30, 2021 to November 15, 2021, and their complicated course of the disease necessitated transfer to the intensive care unit (ICU). The laboratory evaluation included the following: a general blood and urine counts, blood chemistry including urea and creatinine, liver transaminases, and blood coagulogram (prothrombin time (PTT), prothrombin index (PTI), thrombin time, fibrinogen, and blood clotting time).Results. In the group of patients with a fatal outcome on the day of transfer to ICU, lymphocytopenia, eosinopenia, elevated values of creatinine, total bilirubin, transaminases, C-reactive protein, D-dimer, and ferritin were noted. Also on this day, microscopic hematuria, proteinuria and cylindruria were detected in the urine tests of most patients in this group during treatment.Conclusion. Critical deviations in the results of hematological and biochemical tests were revealed. Particular attention should be paid to such parameters as the level of erythrocytes, lymphocytes, eosinophils, glucose, urea, creatinine, total bilirubin, aspartate aminotransferase, alanine aminotransferase, creatine kinase, C-reactive protein, D-dimer, and ferritin.
Collapse
|